Page last updated: 2024-12-06

tiagabine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Tiagabine is a medication used to treat seizures. It is a selective inhibitor of the GABA transporter type 1 (GAT-1), which is responsible for the reuptake of GABA from the synaptic cleft. This results in an increase in the concentration of GABA in the synapse, leading to a reduction in neuronal excitability. Tiagabine was synthesized by researchers at the pharmaceutical company Pfizer in the 1980s. It was originally marketed under the brand name Gabitril. Tiagabine is a highly effective treatment for partial seizures, but it has several side effects, including dizziness, drowsiness, and fatigue. It is also associated with a risk of suicidal thoughts and behaviors. Due to these adverse effects, its use has declined in recent years. Tiagabine is still studied for its potential therapeutic benefits in other neurological disorders, such as epilepsy, anxiety, and pain.'

Tiagabine: A nipecotic acid derivative that acts as a GABA uptake inhibitor and anticonvulsant agent. It is used in the treatment of EPILEPSY, for refractory PARTIAL SEIZURES. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

tiagabine : A piperidinemonocarboxylic acid that is (R)-nipecotic acid in which the hydrogen attached to the nitrogen has been replaced by a 1,1-bis(3-methyl-2-thienyl)but-1-en-4-yl group. A GABA reuptake inhibitor, it is used (generally as the hydrochloride salt) for the treatment of epilepsy. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID60648
CHEMBL ID1027
CHEBI ID9586
SCHEMBL ID34653
MeSH IDM0164774

Synonyms (88)

Synonym
AC-7048
BIDD:GT0018
nnc-050328 free base
CHEMBL1027 ,
no-050328 free base
abt-569 free base
abbott-70569-1
chebi:9586 ,
abbott-70569 free base
a-70569-1
abbott-705691 free base
(r)-1-[4,4-bis-(3-methyl-thiophen-2-yl)-but-3-enyl]-piperidine-3-carboxylic acid
(s)-1-(4,4-bis(3-methylthiophen-2-yl)but-3-enyl)piperidine-3-carboxylic acid
(r)-1-[4,4-bis-(3-methyl-thiophen-2-yl)-but-3-enyl]-piperidine-3-carboxylic acid; hydrochloride
(r)-1-(4,4-bis(3-methylthiophen-2-yl)but-3-enyl)piperidine-3-carboxylic acid hydrochloride
1-[4,4-bis-(3-methyl-4,5-dihydro-thiophen-2-yl)-but-3-enyl]-piperidine-3-carboxylic acid
1-[4,4-bis-(3-methyl-thiophen-2-yl)-but-3-enyl]-piperidine-3-carboxylic acid; hydrochloride
bdbm50039251
abbott-70569
gabitril
(3r)-1-[4,4-bis(3-methyl-2-thienyl)but-3-en-1-yl]piperidine-3-carboxylic acid
no 328
3-piperidinecarboxylic acid, 1-(4,4-bis(3-methyl-2-thienyl)-3-butenyl)-, (r)-
tiagabine [inn:ban]
tiagabinum [inn-latin]
tiagabine [inn]
(-)-(r)-1-(4,4-bis(3-methyl-2-thienyl)-3-butenyl)nipecotic acid
tiagabina [inn-spanish]
115103-54-3
C07503
tiagabine
DB00906
gabitril (tn)
NCGC00164626-01
(3r)-1-[4,4-bis(3-methylthiophen-2-yl)but-3-enyl]piperidine-3-carboxylic acid
D08588
tiagabine (inn)
gabatril
unii-z80i64hmnp
z80i64hmnp ,
(r)-tiagabine
tiagabina
hsdb 7527
no 050328
tiagabinum
S4675
AKOS016011165
bdbm50368628
[3h]tiagabine
(3r)-1-[4,4-bis(3-methylthiophen-2-yl)but-3-en-1-yl]piperidine-3-carboxylic acid
gtpl4818
gtpl4685
PBJUNZJWGZTSKL-MRXNPFEDSA-N
tiagabine [who-dd]
tiagabine [vandf]
3-piperidinecarboxylic acid, 1-(4,4-bis(3-methyl-2-thienyl)-3-buten-1-yl)-, (3r)-
tiagabine [mi]
tiagabine [hsdb]
(3r)-1-(4,4-bis(3-methyl-2-thienyl)-3-buten-1-yl)-3-piperidinecarboxylic acid
HY-B0696
SCHEMBL34653
(r)-(-)-1-[4,4-bis(3-methyl-2-thienyl)-3-butenyl]nipecotic acid
(-)-(r)-1-[4,4-bis(3-methyl-2-thienyl)-3-butenyl]nipecotic acid
(r)-1-(4,4-bis(3-methylthiophen-2-yl)but-3-en-1-yl)piperidine-3-carboxylic acid
DTXSID5023663 ,
no050328
no328
TGB ,
(-)-(r)-1-[4,4-bis(3-methyl-2-thienyl)-3butenyl]nipecotic acid hydrochloride
(r)-1-(4,4-bis(3-methylthiophen-2-yl)but-3-enyl)piperidine-3-carboxylic acid
(r)-n-[4,4-bis(3-methyl-2-thienyl)but-3-en-1-yl]nipecotic acid
1006863-69-9
Q907219
AMY22648
BRD-K60160658-003-08-8
HMS3885J16
CCG-268358
EN300-222195
(3r)-1-[4,4-bis(3-methylthiophen-2-yl)but-3-en-1-yl]piperidine-3-carboxylic acid; gabitril
3-piperidinecarboxylic acid, 1-[4,4-bis(3-methyl-2-thienyl)-3-buten-1-yl]-, (3r)-
(3r)-1-
(3r)-1-(4,4-bis(3-methyl-2-thienyl)but-3-en-1-yl)piperidine-3-carboxylic acid
tiagabinum (inn-latin)
n03ag06
(r)-(-)-1-(4,4-bis(3-methyl-2-thienyl)-3-butenyl)nipecotic acid
dtxcid503663
(-)-(r)-1-
tiagabina (inn-spanish)

Research Excerpts

Overview

Tiagoabine is a novel antiepileptic that acts by increasing synaptic and extracellular gamma-aminobutyric acid concentrations. Tiagabine (Gabitril) is an anticonvulsive drug that binds selectively to GABA transporter-1 and thereby inhibits GABA uptake.

ExcerptReferenceRelevance
"Tiagabine is an antiepileptic drug used for the treatment of partial seizures in humans. "( Antiepileptic Drug Tiagabine Does Not Directly Target Key Cardiac Ion Channels Kv11.1, Nav1.5 and Cav1.2.
Fijałkowski, Ł; Grześk, G; Kowalska, M; Kubacka, M; Nowaczyk, A; Nowaczyk, J; Sałat, K, 2021
)
2.39
"Tiagabine is a novel antiepileptic that acts by increasing synaptic and extracellular gamma-aminobutyric acid concentrations. "( Review of toxicity and trends in the use of tiagabine as reported to US poison centers from 2000 to 2012.
Casavant, MJ; Russell, JL; Spiller, HA; Wiles, D, 2016
)
2.14
"Tiagabine is a well tolerated drug providing effective control of focal seizures and in a sub-population of 25% patients whose cognitive functions were evaluated using MM SE, no significant adverse effect of the drug on such functions was observed."( [Evaluation of the effectiveness of add-on therapy with tiagabine and evaluation of cognitive functions after application of this therapy in patients with drug-resistant focal epilepsy - an observational study (GABI-EPI)].
Halczuk, I; Kaczyński, K; Lipa, A; Mitosek-Szewczyk, K; Sobolewski, P; Stelmasiak, Z, 2015
)
2.11
"Tiagabine (Gabitril) is an anticonvulsive drug that binds selectively to GABA transporter-1 and thereby inhibits GABA uptake."( Development and characterization of [123I]iodotiagabine for in-vivo GABA-transporter imaging.
Beekman, F; Herscheid, J; Hoogland, G; Rijkers, K; Schijns, O; van Kroonenburgh, M; Verbeek, J; Visser-Vandewalle, V, 2013
)
1.37
"Tiagabine (Gabitril) is a GABA uptake inhibitor recently introduced in the United States as an adjunctive treatment for partial complex seizures. "( An open case series on the utility of tiagabine as an augmentation in refractory bipolar outpatients.
Howe, J; Schaffer, CB; Schaffer, LC, 2002
)
2.03
"Tiagabine (TGB) is an anti epileptic drug whose mechanism of action is due to a reduction in the neurone and astrocyte uptake of gamma aminobutyric acid (GABA), causing its concentration at the synapse to be increased."( [Characteristics and indications of tiagabine].
Casas-Fernández, C; Domingo-Jiménez, R, 2002
)
2.03
"Tiagabine proved to be a well-tolerated AED."( Tolerability of tiagabine: a prospective open-label study.
Bauer, J; Bergmann, A; Genton, P; Reuber, M; Stodieck, SR, 2002
)
1.38
"Tiagabine is a potent inhibitor of GABA uptake into neurons and glial cells."( Novel mechanisms of action of three antiepileptic drugs, vigabatrin, tiagabine, and topiramate.
Angehagen, M; Ben-Menachem, E; Hansson, E; Rönnbäck, L, 2003
)
1.27
"Tiagabine (TGB) is a novel anti-epileptic drug providing new therapeutic possibilities to patients with focal seizures resistant to treatment. "( [Determinants of tiagabine (TGB) efficacy and safety. A Polish multicenter study of 1307 patients with focal epilepsy].
Kozik, A; Krause, M,
)
1.91
"Tiagabine appears to be a promising GABAergic medication that moderately improves cocaine-free urines."( Tiagabine increases cocaine-free urines in cocaine-dependent methadone-treated patients: results of a randomized pilot study.
George, TP; Gonsai, K; Gonzalez, G; Kosten, TR; Oliveto, A; Poling, J; Sevarino, K; Sofuoglu, M, 2003
)
2.48
"Tiagabine is an antiepileptic drug, which increases GABA via selective blockade of GABA reuptake."( Effects of tiagabine on cholecystokinin-tetrapeptide (CCK-4)-induced anxiety in healthy volunteers.
Baghai, TC; Ella, R; Eser, D; Möller, HJ; Padberg, F; Rötzer, F; Rupprecht, R; Schule, C; Zwanzger, P, 2003
)
1.43
"Tiagabine (Gabitril) is a unique anticonvulsant that is prescribed for a variety of psychiatric disorders. "( Intentional overdose with tiagabine: an unusual clinical presentation.
Cantrell, FL; Himes, E; Ritter, M, 2004
)
2.07
"Tiagabine is a unique antiepileptic drug with a novel mechanism of action. "( The pharmacokinetic inter-relationship of tiagabine in blood, cerebrospinal fluid and brain extracellular fluid (frontal cortex and hippocampus).
Patsalos, PN; Ratnaraj, N; Wang, X, 2004
)
2.03
"Tiagabine hydrochloride acts as a selective GABA reuptake inhibitor (SGRI)."( Low-dose tiagabine effectiveness in anxiety disorders.
Rawlings, D; Schaller, JL; Thomas, J, 2004
)
1.46
"Tiagabine is a new antiepileptic drug which acts via selective blockade of GABA reuptake."( Saccadic eye velocity after selective GABAergic treatment with tiagabine in healthy volunteers.
Baghai, TC; Ella, R; Eser, D; Kathmann, N; Moller, HJ; Padberg, F; Rupprecht, R; Schule, C; Zwanzger, P, 2005
)
1.29
"Tiagabine is an anticonvulsant gamma-aminobutyric acid reuptake inhibitor commonly used as an add-on treatment of refractory partial seizures in persons over 12 years old. "( Tiagabine may reduce bruxism and associated temporomandibular joint pain.
Kast, RE, 2005
)
3.21
"Tiagabine (TGB) is a new antiepileptic drug with a unique mechanism of action, with efficacy and tolerance confirmed in many randomized, placebo-controlled add-on trials in patients with partial epilepsy. "( [GEOS (Gabitril Epilepsy Observational Study) -- Polish results of the international study of tiagabine in partial epilepsy].
Niedzielska, K,
)
1.79
"Tiagabine is an anticonvulsant that blocks reuptake of the inhibitory neurotransmitter GABA. "( Retrospective evaluation of tiagabine overdose.
Anderson, DL; Krenzelok, EP; Kumar, S; Ryan, M; Spiller, HA; Thompson, M; Winter, ML, 2005
)
2.07
"Tiagabine is an antiepileptic drug used as adjunctive therapy for partial seizures that is believed to selectively inhibit the presynaptic reuptake of gamma aminobutyric acid (GABA). "( Tiagabine overdose: a case of status epilepticus in a non-epileptic patient.
Fulton, JA; Hoffman, RS; Nelson, LS, 2005
)
3.21
"Tiagabine is a new generation antiepileptic drug, a specific inhibitor of gamma-aminobutiric acid (GABA) reuptake from the synaptic space to neurons and glia. "( Effect of combined administration of ethanol and tiagabine on rabbit EEG.
Czarnecka, E; Pietrzak, B,
)
1.83
"Tiagabine is a GABA uptake inhibitor that has been shown to produce acute behavioral effects in animals."( Effects of acute tiagabine administration on aggressive responses of adult male parolees.
Cherek, DR; Lane, SD; Lieving, LM; Nouvion, SO; Tcheremissine, OV, 2008
)
1.41
"Tiagabine is a derivative of nipecotinic acid used in the therapy of partial seizures, partial seizures with secondary generalization, stress disorder, psychosis and cocaine dependence. "( [Tiagabine overdose--report of two cases].
Chodorowski, Z; Kosińska-Tomczyk, H; Sein Anand, J; Wiśniewski, M, 2007
)
2.69
"Tiagabine is an anticonvulsant acting by selective inhibition of neuronal and glial gamma-aminobutyric acid uptake, resulting in increased gamma-aminobutyric acid-mediated inhibition in the brain. "( Deliberate self-poisoning with tiagabine: an unusual toxidrome.
Daly, FF; Forbes, RA; Hackett, LP; Kalra, H, 2007
)
2.07
"Tiagabine (TGB) is a novel antiepileptic that decreases GABA uptake. "( Seizures in a pediatric patient with a tiagabine overdose.
Jones, CC; Kazzi, ZN; Morgan, BW, 2006
)
2.05
"Tiagabine is an anticonvulsant drug which may also have sleep-enhancing properties. "( Discriminative stimulus effects of tiagabine and related GABAergic drugs in rats.
Hutson, PH; McDonald, LM; Sheppard, WF; Sohal, B; Staveley, SM; Tattersall, FD, 2008
)
2.07
"Tiagabine is a new antiepileptic drug which acts by a novel mechanism, inhibiting the reuptake of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) into neurons and glia. "( Adjunctive treatment of partial seizures with tiagabine: a placebo-controlled trial.
Chadwick, DW; Dam, M; Duncan, JS; Gram, L; McKelvy, JF; Mengel, H; Mikkelsen, M; Morrow, J; Richens, A; Shu, V, 1995
)
1.99
"Tiagabine is a novel antiepileptic drug which acts by decreasing gamma aminobutyric acid uptake in astrocytes and neurones. "( Deliberate overdose with the novel anticonvulsant tiagabine.
Brodie, MJ; Leach, JP; Stolarek, I, 1995
)
1.99
"Tiagabine is a new anticonvulsant drug that blocks the uptake of GABA, prolonging the action of this inhibitory transmitter. "( Blockade of GABA uptake with tiagabine inhibits audiogenic seizures and reduces neuronal firing in the inferior colliculus of the genetically epilepsy-prone rat.
Anderson, CA; Faingold, CL; Randall, ME, 1994
)
2.02
"Tiagabine is a novel antiepileptic drug that was designed to block gamma-aminobutyric acid uptake by presynaptic neurons and glial cells. "( Tiagabine.
Shinnar, S, 1997
)
3.18
"Tiagabine (TGB) is a novel antiepileptic drug whose anticonvulsant effects are due to inhibition of gamma-aminobutyric acid (GABA) transport mediated by the GABA transporter-1. "( Tiagabine exerts an anti-epileptogenic effect in amygdala kindling epileptogenesis in the rat.
Dalby, NO; Nielsen, EB, 1997
)
3.18
"Tiagabine is a novel antiepileptic drug which has clinical efficacy against complex refractory and myoclonic seizures. "( Comparison of the preclinical anticonvulsant profiles of tiagabine, lamotrigine, gabapentin and vigabatrin.
Dalby, NO; Nielsen, EB, 1997
)
1.98
"Tiagabine is a gamma-aminobutyric acid (GABA) uptake inhibitor which is structurally related to nipecotic acid but has an improved ability to cross the blood-brain barrier. "( Tiagabine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of epilepsy.
Adkins, JC; Noble, S, 1998
)
3.19
"Tiagabine is a potent GABA uptake inhibitor with demonstrated anticonvulsant activity. "( Inhibitory nature of tiagabine-augmented GABAA receptor-mediated depolarizing responses in hippocampal pyramidal cells.
Capek, R; Esplin, B; Jackson, MF, 1999
)
2.07
"Tiagabine (TGB) is a recently approved antiepileptic drug (AED) that inhibits y-aminobutyric acid (GABA) reuptake into neurons and glia, a mechanism of action that is specific and unique among the AEDs. "( Tiagabine.
Schachter, SC, 1999
)
3.19
"Tiagabine is a new antiepileptic drug that inhibits the uptake of gamma-aminobutyric acid into neurons and glia. "( Tiagabine: absence of kinetic or dynamic interactions with ethanol.
Cole, G; Jansen, JA; Kastberg, H; Wesnes, K, 1998
)
3.19
"Tiagabine is a new antiepileptic drug which acts by blocking neuronal and glial GABA uptake and it is indicated in the treatment of partial epilepsies. "( [Clinical implications of pharmacology and pharmacokinetics of tiagabine].
Pita-Calandre, E,
)
1.81
"Tiagabine appeared to be an effective and safe drug in resistant epilepsy in children below 12 years of age."( [Tiagabine in drug-resistant epilepsy in children: preliminary study].
Popielarczyk, M; Sokołowska, D; Wendorff, J; Zubiel, M, 2000
)
2.66
"Tiagabine (TGB) is a novel antiepileptic drug efficacious for the treatment of partial epilepsies. "( [Long-term safety of using tiagabine in epilepsy].
Kozik, A, 2000
)
2.05
"Tiagabine (TGB) is a new antiepileptic drug (AED) with gamma-aminobutyric acid (GABA)ergic mechanism of action. "( Transient dystonias in three patients treated with tiagabine.
Grabowska-Grzyb, A; Wolańczyk, T, 2001
)
2.01
"Tiagabine is an effective, well tolerated drug when used as additional treatment in patients with partial epilepsy."( [An open study of tiagabine in partial epilepsy].
Arroyo, S; Salas-Puig, J,
)
1.91
"Tiagabine is a relatively new anticonvulsive agent. "( [Experience with tiagabine in the clinical practice; new insights as to the efficacy and safety profile].
Kellinghaus, C; Loddenkemper, T; Lüdemann, P; Weitemeyer, L, 2001
)
2.09

Effects

Tiagabine has an increased affinity, specificity, and is not transported intracellularly via the GABA uptake carrier. It has been shown to increase SWS in favor of REM sleep without impacting subjective sleep. TiagAbine has a benign adverse-effect profile, is easily tolerated, and retains effectiveness over time.

ExcerptReferenceRelevance
"Tiagabine has a benign adverse-effect profile, is easily tolerated, and retains effectiveness over time."( Tiagabine may reduce bruxism and associated temporomandibular joint pain.
Kast, RE, 2005
)
2.49
"Tiagabine has been shown to increase SWS in favor of REM sleep without impacting subjective sleep."( Slow wave sleep induced by GABA agonist tiagabine fails to benefit memory consolidation.
Binkofski, F; Born, J; Feld, GB; Groch, S; Ma, Y; Mölle, M; Wilhelm, I, 2013
)
1.38
"Tiagabine has a benign adverse-effect profile, is easily tolerated, and retains effectiveness over time."( Tiagabine may reduce bruxism and associated temporomandibular joint pain.
Kast, RE, 2005
)
2.49
"Tiagabine has comparable anticonvulsant action to carbamazepine in rats and has anticonvulsant effects in non-human primates supporting the potential use of inhibitors of GABA uptake as therapy for epilepsy."( The gamma-aminobutyric acid uptake inhibitor, tiagabine, is anticonvulsant in two animal models of reflex epilepsy.
Chapman, AG; Meldrum, BS; Parvez, NS; Smith, SE, 1995
)
1.27
"[3H]Tiagabine has several major advantages over the currently utilized radioligand for the GABA uptake carrier [3H]nipecotic acid, in that [3H]tiagabine has an increased affinity, specificity, and is not transported intracellularly via the GABA uptake carrier."( Quantitative autoradiographic characterization of the binding of [3H]tiagabine (NNC 05-328) to the GABA uptake carrier.
Andersen, KE; Foged, C; Suzdak, PD, 1994
)
1
"Tiagabine has shown promising efficacy and safety profiles as add-on treatment for partial seizures."( Long-term cognitive and EEG effects of tiagabine in drug-resistant partial epilepsy.
Aikiä, M; Kälviäinen, R; Mervaala, E; Pitkänen, A; Riekkinen, PJ; Saukkonen, AM, 1996
)
1.28
"Tiagabine has demonstrated a good safety profile and, while it has not been demonstrated to be superior to other second-line AEDs for partial seizures, its safety and select mechanism of action warrant its further evaluation in the clinical setting. "( Tiagabine: a novel antiepileptic drug.
Luer, MS; Rhoney, DH, 1998
)
3.19
"Tiagabine has shown no clinically important interactions with other drugs, including oral contraceptives."( Tiagabine: a new therapeutic option for people with intellectual disability and partial epilepsy.
Kälviäinen, R, 1998
)
2.46
"Tiagabine has recently been introduced into clinical use as an anti-epileptic drug."( Effects of tiagabine and diazepam on operant ethanol self-administration in the rat.
Heilig, M; Rimondini, R; Sommer, W, 2002
)
1.43

Actions

Tiagabine appeared to produce a sustained reduction in seizure frequency in studies of up to 12 months' duration. The tiagabne-induced increase in the amplitude of the EEG 11.5-30 Hz frequency band (beta), was used as pharmacodynamic endpoint.

ExcerptReferenceRelevance
"Tiagabine appeared to produce a sustained reduction in seizure frequency in studies of up to 12 months' duration."( Tiagabine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of epilepsy.
Adkins, JC; Noble, S, 1998
)
2.46
"The tiagabine-induced increase in the amplitude of the EEG 11.5-30 Hz frequency band (beta), was used as pharmacodynamic endpoint."( Application of a combined "effect compartment/indirect response model" to the central nervous system effects of tiagabine in the rat.
Cleton, A; Danhof, M; de Greef, HJ; Edelbroek, PM; Voskuyl, RA, 1999
)
1
"2. ++Tiagabine produced an increase in the amplitude of the 11.5 - 30 Hz frequency band of the EEG."( Effect of amygdala kindling on the central nervous system effects of tiagabine: EEG effects versus brain GABA levels.
Altorf, BA; Cleton, A; Danhof, M; Voskuyl, RA, 2000
)
1
"Tiagabine may cause various mild extrapyramidal side effects. "( Transient dystonias in three patients treated with tiagabine.
Grabowska-Grzyb, A; Wolańczyk, T, 2001
)
2.01

Treatment

Tiagoabine treatment did not affect the heart rate or blood pressure changes induced by nicotine. Treatment with tiagabine led to a significant increase in 3alpha,5alpha-tetrahydrodeoxycorticosterone.

ExcerptReferenceRelevance
"Tiagabine-treated rats were indistinguishable (P > 0.05) from controls in tissue amino acid levels and in (13)C enrichments from [2-(13)C]acetate."( Effects of γ-Aminobutyric acid transporter 1 inhibition by tiagabine on brain glutamate and γ-Aminobutyric acid metabolism in the anesthetized rat In vivo.
Behar, KL; de Graaf, RA; Patel, AB; Rothman, DL, 2015
)
1.38
"Tiagabine treatment did not affect the heart rate or blood pressure changes induced by nicotine. "( Effects of tiagabine in combination with intravenous nicotine in overnight abstinent smokers.
Culligan, K; Kosten, T; Mouratidis, M; Sofuoglu, M; Yoo, S, 2005
)
2.16
"Tiagabine treatment did not affect the cocaine-induced blood pressure and heart rate changes."( Tiagabine affects the subjective responses to cocaine in humans.
Kosten, TR; Mitchell, E; Poling, J; Sofuoglu, M, 2005
)
2.49
"Tiagabine treatment did not cause deterioration in cognitive performance or produce any rhythmic slow-wave activity or other constant, new abnormalities on EEG during longer follow-up with successful treatment on higher doses after 6-12 months (mean 65.7 mg/day, range 30-80 mg/day) and after 18-24 months (mean dose 67.6 mg/day, range 24-80 mg/day)."( Long-term cognitive and EEG effects of tiagabine in drug-resistant partial epilepsy.
Aikiä, M; Kälviäinen, R; Mervaala, E; Pitkänen, A; Riekkinen, PJ; Saukkonen, AM, 1996
)
1.28
"Treatment with tiagabine led to a significant increase in 3alpha,5alpha-tetrahydrodeoxycorticosterone (3alpha,5alpha-THDOC) from 0.49 to 1.42 nmol/l (Z=-2.80, p=.005), which was significantly correlated with a decrease of panic symptoms in the CCK-4 challenge."( Changes in CCK-4 induced panic after treatment with the GABA-reuptake inhibitor tiagabine are associated with an increase in 3alpha,5alpha-tetrahydrodeoxycorticosterone concentrations.
Baghai, TC; di Michele, F; Eser, D; Padberg, F; Pasini, A; Romeo, E; Rupprecht, R; Zwanzger, P, 2009
)
0.92
"Treatment with tiagabine was generally well tolerated."( Tiagabine for posttraumatic stress disorder: a case series of 7 women.
Taylor, FB, 2003
)
2.1
"Treatment with tiagabine had no significant effect on SEV and saccade amplitude."( Saccadic eye velocity after selective GABAergic treatment with tiagabine in healthy volunteers.
Baghai, TC; Ella, R; Eser, D; Kathmann, N; Moller, HJ; Padberg, F; Rupprecht, R; Schule, C; Zwanzger, P, 2005
)
0.91
"Pretreatment with tiagabine (2.5-5 mg/kg) produced a rightward shift of a heroin dose-response curve, while vigabatrin (75-300 mg/kg), baclofen (0.5-2.5 mg/kg) or muscimol (0.5-2 mg/kg) given prior to heroin (0.0625-0.5 mg/kg) failed to alter heroin discrimination."( Role of opioidergic mechanisms and GABA uptake inhibition in the heroin-induced discriminative stimulus effects in rats.
Filip, M; Krówka, T; Przewłocki, R; Solecki, W,
)
0.45
"In untreated rats, tiagabine and topiramate caused a moderate increase of hepatic pentoxyresorufin-O-dealkylase activity (approximately 100 and 200 pmol/min./mg respectively, controls 15 pmol/min./mg)."( Effect of tiagabine and topiramate on porphyrin metabolism in an in vivo model of porphyria.
Krijt, J; Krijtová, H; Sanitrák, J, 2001
)
1.03

Toxicity

Tiagabine is a safe and efficient anti-epileptic drug for children and adults with focal epilepsy.

ExcerptReferenceRelevance
" Discontinuation resulting from adverse events were infrequent, occurring in 15% of patients receiving TGB compared to 5% receiving placebo."( Tiagabine: the safety landscape.
Leppik, IE, 1995
)
1.73
"Standard antiepileptic drugs (AEDs) are associated with a wide variety of acute and chronic adverse events and with many interactions with each other and with non-AEDs that complicate patient management."( Overview of the safety of newer antiepileptic drugs.
Shorvon, S; Stefan, H, 1997
)
0.3
" Adverse events observed included dizziness, tremor, nausea, somnolence, incoordination, and unsteady gait."( Pharmacokinetics and safety of tiagabine in subjects with various degrees of hepatic function.
El-Shourbagy, T; Gustavson, LE; Lam, NP; Lau, AH; Layden, T; Qian, JX; Sperelakis, R, 1997
)
0.58
" The patients should be monitored closely for potential neurologic adverse events."( Pharmacokinetics and safety of tiagabine in subjects with various degrees of hepatic function.
El-Shourbagy, T; Gustavson, LE; Lam, NP; Lau, AH; Layden, T; Qian, JX; Sperelakis, R, 1997
)
0.58
" Adverse effects were usually mild and involved the nervous system."( Safety of tiagabine: summary of 53 trials.
Deaton, R; Gram, L; Leppik, IE; Sommerville, KW, 1999
)
0.71
" We classified all adverse events based on severity and persistence, and recorded the dose at onset of each adverse event."( Safety of long-term treatment with tiagabine.
Abou-Khalil, B; Fakhoury, T; Uthman, B, 2000
)
0.58
" The most common adverse effects are dizziness, asthenia, nervousness, tremor, diarrhoea and depression."( [Long-term safety of using tiagabine in epilepsy].
Kozik, A, 2000
)
0.6
" The number and character of adverse effects observed in the course of the present study did not differ from these noted in long-term Gabitril trials."( [Open multicenter study of the effectiveness and safety of gabitril in epileptic patients with partial seizures].
Czapiński, P; Grygolec, P; Jedrzejczak, J; Kozik, A; Sobaniec, W; Wendorff, J, 2000
)
0.31
" Eight (22%) patients receiving TGB during the double-blind phase reported adverse events, of which dizziness and incoordination were the most frequent."( Tiagabine: efficacy and safety in adjunctive treatment of partial seizures.
Brown, S; Crawford, P; Lassen, LC; Meinardi, H; Pedersen, B; Pedersen, PC; Rentmeester, TW, 2001
)
1.75
" Central nervous system (CNS)-related adverse effects, most frequently dizziness, were common with TGB treatment during the titration period; the risk became similar to placebo rates during fixed-dose periods."( Long-term safety of tiagabine.
Kälviäinen, R, 2001
)
0.63
" Effect and adverse events were registered according to documentation of routine visits in the outpatient clinic."( [Experience with tiagabine in the clinical practice; new insights as to the efficacy and safety profile].
Kellinghaus, C; Loddenkemper, T; Lüdemann, P; Weitemeyer, L, 2001
)
0.65
"Doctors should advise patients of recognised adverse events of proposed therapy."( Ethical dilemmas of potential adverse events.
Beran, RG, 2001
)
0.31
" Tiagabine is a safe and efficient anti-epileptic drug for children and adults with focal epilepsy."( [Determinants of tiagabine (TGB) efficacy and safety. A Polish multicenter study of 1307 patients with focal epilepsy].
Kozik, A; Krause, M,
)
1.38
" Five hundred micromolar GABA and 50 microM tiagabine were not toxic in the presence or absence of light."( Acute vigabatrin retinotoxicity in albino rats depends on light but not GABA.
Benz, AM; Ishikawa, M; Izumi, M; Izumi, Y; Thio, LL; Zorumski, CF, 2004
)
0.58

Pharmacokinetics

No statistically significant differences in maximum plasma concentration (Cmax), area under the concentration-time curve (AUC tau), or half-life (t1/2) were observed when tiagabine was administered alone or in combination with erythromycin. Small decreases in mean valproic acid Cmax and AUC0-tau are probably of limited clinical importance, given the broad therapeutic range of valproate (50-100 microg/mL)

ExcerptReferenceRelevance
" Pharmacokinetic parameters were calculated by standard noncompartmental methods."( Pharmacokinetics of tiagabine, a gamma-aminobutyric acid-uptake inhibitor, in healthy subjects after single and multiple doses.
Gustavson, LE; Mengel, HB, 1995
)
0.61
" Three of the new drugs, gabapentin, topiramate and vigabatrin, are more promising on the basis of their pharmacokinetic features."( Comparative pharmacokinetics of the newer antiepileptic drugs.
Bialer, M, 1993
)
0.29
" When used as a monotherapy, topiramate is eliminated primarily in the urine in an unchanged form with a half-life of 20 to 30 hours; elimination is faster in patients receiving concurrent medication with enzyme-inducing anticonvulsants, in whom the extent of biotransformation becomes more prominent."( The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine.
Bialer, M; Perucca, E, 1996
)
0.51
"This article surveys the pharmacokinetic parameters for the new antiepileptic drugs (AEDs): felbamate, gabapentin, lamotrigine, oxcarbazepine, tiagabine, topiramate, and vigabatrin."( Pharmacokinetics of new antiepileptic drugs.
Gram, L, 1996
)
0.49
" Plasma tiagabine concentrations were determined by high-performance liquid chromatography; pharmacokinetic parameters were calculated using noncompartmental methods."( Pharmacokinetics of tiagabine as add-on therapy in patients taking enzyme-inducing antiepilepsy drugs.
Cascino, GD; Graves, NM; Gustavson, LE; Leppik, IE; Pixton, GC; So, EL; Wolff, D, 1995
)
1.05
" Dose-normalized Cmax was higher in children taking valproate (18."( A single-dose study to define tiagabine pharmacokinetics in pediatric patients with complex partial seizures.
Boellner, SW; el-Shourbagy, T; Granneman, GR; Guenther, HJ; Gustavson, LE; Qian, JX; Sommerville, KW, 1997
)
0.59
" Pharmacokinetic parameters were compared between the groups by analysis of covariance."( Pharmacokinetics and safety of tiagabine in subjects with various degrees of hepatic function.
El-Shourbagy, T; Gustavson, LE; Lam, NP; Lau, AH; Layden, T; Qian, JX; Sperelakis, R, 1997
)
0.58
" The pharmacokinetic parameters of tiagabine following single- and multiple-dose administration were similar in both healthy elderly and young volunteers except for a small but significant difference in the area under the concentration-time curve after multiple-doses (103 +/- 29 ng."( The pharmacokinetics of tiagabine in healthy elderly volunteers and elderly patients with epilepsy.
Jansen, JA; Larsen, S; Mengel, HB; Richens, A; Snel, S, 1997
)
0.88
" The pharmacokinetics of TGB were similar in all subjects; no pharmacokinetic parameter (based on either total or unbound concentrations) was statistically correlated with creatinine clearance."( Effect of renal impairment on the pharmacokinetics and tolerability of tiagabine.
Cato, A; El-Shourbagy, T; Gustavson, LE; Kelly, EA; Qian, J, 1998
)
0.53
"A sparse sampling method is proposed to assess pharmacokinetic parameters after a single dose of the antiepilepsy drug tiagabine."( Development of a limited sampling approach in pharmacokinetic studies: experience with the antiepilepsy drug tiagabine.
Mahmood, I, 1998
)
0.72
"To assess the possibility of any clinically relevant pharmacokinetic interactions between tiagabine, a novel antiepileptic drug, and digoxin."( Tiagabine, a novel antiepileptic agent: lack of pharmacokinetic interaction with digoxin.
Jansen, JA; Jonkman, JH; Pedersen, PC; Snel, S; van Heiningen, PN, 1998
)
1.96
"Potential pharmacokinetic interactions between tiagabine and digoxin were investigated in an open-label, two-period cross-over study in healthy male volunteers."( Tiagabine, a novel antiepileptic agent: lack of pharmacokinetic interaction with digoxin.
Jansen, JA; Jonkman, JH; Pedersen, PC; Snel, S; van Heiningen, PN, 1998
)
2
"No statistically significant differences between treatment groups were observed for any of the derived digoxin pharmacokinetic parameters."( Tiagabine, a novel antiepileptic agent: lack of pharmacokinetic interaction with digoxin.
Jansen, JA; Jonkman, JH; Pedersen, PC; Snel, S; van Heiningen, PN, 1998
)
1.74
"At the doses administered, there is no evidence of a pharmacokinetic interaction between digoxin and tiagabine in healthy male volunteers."( Tiagabine, a novel antiepileptic agent: lack of pharmacokinetic interaction with digoxin.
Jansen, JA; Jonkman, JH; Pedersen, PC; Snel, S; van Heiningen, PN, 1998
)
1.96
" A one-compartment model with first-order absorption and elimination was used to fit the TGB plasma concentration-time data, with a population pharmacokinetic approach."( Population analysis of the pharmacokinetics of tiagabine in patients with epilepsy.
El-Shourbagy, T; Granneman, GR; Gustavson, LE; Locke, C; Samara, EE; Sommerville, KW, 1998
)
0.56
" No statistically significant differences in maximum plasma concentration (Cmax), area under the concentration-time curve (AUC tau), or half-life (t1/2) of tiagabine were observed when tiagabine was administered alone or in combination with erythromycin."( Lack of pharmacokinetic interaction between tiagabine and erythromycin.
Agersø, H; Groes, L; Kruse, T; Thomsen, MS, 1998
)
0.76
" The pharmacokinetic assessment was repeated on day 18."( Lack of pharmacokinetic drug interactions between tiagabine and carbamazepine or phenytoin.
Boellner, SW; Cao, GX; Cato, A; Guenther, HJ; Gustavson, LE; Qian, JX; Sommerville, KW, 1998
)
0.55
" The small decreases in mean valproic acid Cmax and AUC0-tau observed during the concomitant administration of tiagabine and valproate are probably of limited clinical importance, given the broad therapeutic range of valproate (50-100 microg/mL)."( Lack of a clinically significant pharmacokinetic drug interaction between tiagabine and valproate.
Boellner, SW; Granneman, GR; Guenther, HJ; Gustavson, LE; Sommerville, KW; Witt, GF, 1998
)
0.74
" For all drugs that are metabolized, half-life is shortened and clearance is increased when patients receive concomitant enzyme-inducing agents such as barbiturates, phenytoin, and carbamazepine."( The clinical pharmacokinetics of the new antiepileptic drugs.
Perucca, E, 1999
)
0.3
" Renal impairment does not alter the pharmacokinetic profile of tiagabine; hepatic disease, however, significantly reduces tiagabine elimination and lower daily doses of the drug are necessary in these patients."( [Clinical implications of pharmacology and pharmacokinetics of tiagabine].
Pita-Calandre, E,
)
0.61
"5-30 Hz) of the EEG as derived by fast Fourier transformation analysis was used as pharmacodynamic endpoint."( Pharmacokinetic-pharmacodynamic modelling of tiagabine CNS effects upon chronic treatment in rats: lack of change in concentration-EEG effect relationship.
Altorf, BA; Cleton, A; Danhof, M; Voskuyl, RA, 2000
)
0.57
" In the meantime, a review of the established pharmacokinetic and pharmacodynamic activities of these agents is the first step in defining their optimal uses and limitations in the psychiatric setting."( Pharmacokinetics of new anticonvulsants in psychiatry.
Morris, HH, 1998
)
0.3
"The objective of this study was to characterize quantitatively the pharmacodynamic interaction between midazolam (MDL), an allosteric modulator of the gamma-aminobutyric acid subtype A (GABAA) receptor, and tiagabine (TGB), an inhibitor of synaptic GABA uptake."( Pharmacodynamic analysis of the interaction between tiagabine and midazolam with an allosteric model that incorporates signal transduction.
Danhof, M; Edelbroek, PM; Jonker, DM; Piotrovsky, VK; Vermeij, DA; Voskuyl, RA, 2003
)
0.76
"5- to 30-Hz frequency band was used as the pharmacodynamic end point."( Pharmacodynamic analysis of the interaction between tiagabine and midazolam with an allosteric model that incorporates signal transduction.
Danhof, M; Edelbroek, PM; Jonker, DM; Piotrovsky, VK; Vermeij, DA; Voskuyl, RA, 2003
)
0.57
" A significant pharmacokinetic interaction with TGB was observed."( Pharmacodynamic analysis of the interaction between tiagabine and midazolam with an allosteric model that incorporates signal transduction.
Danhof, M; Edelbroek, PM; Jonker, DM; Piotrovsky, VK; Vermeij, DA; Voskuyl, RA, 2003
)
0.57
"We conclude that the in vivo pharmacodynamic interaction between MDL and TGB is additive rather than synergistic."( Pharmacodynamic analysis of the interaction between tiagabine and midazolam with an allosteric model that incorporates signal transduction.
Danhof, M; Edelbroek, PM; Jonker, DM; Piotrovsky, VK; Vermeij, DA; Voskuyl, RA, 2003
)
0.57
"The pharmacokinetic properties of a drug are the primary deter-minant of the extent and duration of drug action, and influence susceptibility to clinically important drug interactions."( The ideal pharmacokinetic properties of an antiepileptic drug: how close does levetiracetam come?
Johannessen, SI; Perucca, E, 2003
)
0.32
"The pharmacodynamic interaction between the antiepileptic drugs (AEDs) tiagabine (TGB) and lamotrigine (LTG) was characterized on basis of the anticonvulsant effect in the cortical stimulation model in the rat."( Pharmacodynamic analysis of the anticonvulsant effects of tiagabine and lamotrigine in combination in the rat.
Danhof, M; Jonker, DM; Voskuyl, RA, 2004
)
0.8
" A potential pharmacokinetic interaction was accounted for by determination of total plasma concentrations of both drugs."( Pharmacodynamic analysis of the anticonvulsant effects of tiagabine and lamotrigine in combination in the rat.
Danhof, M; Jonker, DM; Voskuyl, RA, 2004
)
0.57
" This analysis showed that the pharmacodynamic interaction between TGB and LTG is synergistic for the ictal signs of eye closure and head jerk."( Pharmacodynamic analysis of the anticonvulsant effects of tiagabine and lamotrigine in combination in the rat.
Danhof, M; Jonker, DM; Voskuyl, RA, 2004
)
0.57
"This study demonstrates the usefulness of ictal-component analysis for studying the pharmacodynamic interaction between AEDs."( Pharmacodynamic analysis of the anticonvulsant effects of tiagabine and lamotrigine in combination in the rat.
Danhof, M; Jonker, DM; Voskuyl, RA, 2004
)
0.57
" Entry of tiagabine into brain ECF (frontal cortex and hippocampus) was rapid with Tmax values of 31-46 min."( The pharmacokinetic inter-relationship of tiagabine in blood, cerebrospinal fluid and brain extracellular fluid (frontal cortex and hippocampus).
Patsalos, PN; Ratnaraj, N; Wang, X, 2004
)
0.99
" For drugs that are eliminated renally completely unchanged (gabapentin, pregabalin and vigabatrin) or mainly unchanged (levetiracetam and topiramate), the pharmacokinetic variability is less pronounced and more predictable."( Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed?
Johannessen, SI; Tomson, T, 2006
)
0.33
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" In contrast, levetiracetam was without affect on tiagabine or vigabatrin concentrations and co-administration with gabapentin, tiagabine or vigabatrin had no effect on levetiracetam brain concentrations, indicating the pharmacodynamic nature of interaction between these antiepileptic drugs in the mouse pentylenetetrazole model."( Pharmacodynamic and pharmacokinetic interaction profiles of levetiracetam in combination with gabapentin, tiagabine and vigabatrin in the mouse pentylenetetrazole-induced seizure model: an isobolographic analysis.
Andres-Mach, MM; Czuczwar, SJ; Dudra-Jastrzebska, M; Luszczki, JJ; Patsalos, PN; Ratnaraj, N; Sielski, M, 2009
)
0.82
" Serum and brain levels of antiepileptic drugs and cannabidiol were determined by using HPLC in order to ascertain any pharmacokinetic contribution to the observed behavioral effects."( Acute effect of cannabidiol on the activity of various novel antiepileptic drugs in the maximal electroshock- and 6 Hz-induced seizures in mice: Pharmacodynamic and pharmacokinetic studies.
Nieoczym, D; Socała, K; Szafarz, M; Wlaź, P; Wyska, E, 2019
)
0.51

Compound-Compound Interactions

ExcerptReferenceRelevance
" There were no statistically significant differences in carbamazepine, carbamazepine epoxide, and phenytoin pharmacokinetic parameters when either drug was administered alone or in combination with tiagabine."( Lack of pharmacokinetic drug interactions between tiagabine and carbamazepine or phenytoin.
Boellner, SW; Cao, GX; Cato, A; Guenther, HJ; Gustavson, LE; Qian, JX; Sommerville, KW, 1998
)
0.74
" Measurement of total brain antiepileptic drug concentrations revealed that levetiracetam in combination with gabapentin at the fixed-ratio of 1:4 significantly elevated (21%) total brain gabapentin concentrations."( Pharmacodynamic and pharmacokinetic interaction profiles of levetiracetam in combination with gabapentin, tiagabine and vigabatrin in the mouse pentylenetetrazole-induced seizure model: an isobolographic analysis.
Andres-Mach, MM; Czuczwar, SJ; Dudra-Jastrzebska, M; Luszczki, JJ; Patsalos, PN; Ratnaraj, N; Sielski, M, 2009
)
0.57

Bioavailability

ExcerptReferenceRelevance
" It is well absorbed from the gastrointestinal tract and negligibly bound to plasma proteins."( The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine.
Bialer, M; Perucca, E, 1996
)
0.51
" After oral administration, absorption is rapid and relatively efficient for the new AEDs, the most notable exception being gabapentin, whose bioavailability decreases with increasing dosage."( The clinical pharmacokinetics of the new antiepileptic drugs.
Perucca, E, 1999
)
0.3
" Human oral bioavailability is an important pharmacokinetic property, which is directly related to the amount of drug available in the systemic circulation to exert pharmacological and therapeutic effects."( Hologram QSAR model for the prediction of human oral bioavailability.
Andricopulo, AD; Moda, TL; Montanari, CA, 2007
)
0.34
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36
"These data show that treatment with orally bioavailable GABA-mimetic drugs if combined with spinal-segment-specific GAD65 gene overexpression can represent a novel and highly effective anti-spasticity treatment which is associated with minimal side effects and is restricted to GAD65-gene over-expressing spinal segments."( Combinational spinal GAD65 gene delivery and systemic GABA-mimetic treatment for modulation of spasticity.
Galik, J; Hefferan, MP; Juhas, S; Juhasova, J; Kakinohana, O; Kucharova, K; Lazar, P; Marsala, M; Marsala, S; Miyanohara, A; Motlik, J; Nejime, T; Platoshyn, O; Strnadel, J; Vinay, L, 2012
)
0.38

Dosage Studied

Tiagabine is efficacious and well tolerated as adjunctive therapy for CPS. There is a clear dose-response relationship. In acute anxiety treatment, very low initial dosing with gradual increases may be sufficient for anxiety effects.

ExcerptRelevanceReference
" A clear dose-response has been demonstrated, and the minimal effective dose level is 30 mg."( International experience with tiagabine add-on therapy.
Ben-Menachem, E, 1995
)
0.58
" We used in vivo microdialysis to determine a suitable dosing regimen for tiagabine (NNC328) to elevate extracellular levels of GABA within the hippocampus."( Postischemic inhibition of GABA reuptake by tiagabine slows neuronal death in the gerbil hippocampus.
Inglefield, JR; Perry, JM; Schwartz, RD, 1995
)
0.78
" Specific indications and dosage schedules have been provided."( New antiepileptic drugs.
Brodie, MJ; Wilson, EA, 1996
)
0.29
" We evaluated the cognitive and quality of life effects of tiagabine in a double-blind, add-on, placebo-controlled, parallel, multicenter, dose-response efficacy study in patients with focal epilepsy whose complex partial seizures were difficult to control."( Cognitive and quality of life effects of differing dosages of tiagabine in epilepsy.
Arnett, JL; Dodrill, CB; Shu, V; Sommerville, KW, 1997
)
0.78
"Because of the decreased drug elimination caused by liver function impairment, reduced doses or increased dosing interval or both may be needed to attain therapeutic plasma drug concentrations."( Pharmacokinetics and safety of tiagabine in subjects with various degrees of hepatic function.
El-Shourbagy, T; Gustavson, LE; Lam, NP; Lau, AH; Layden, T; Qian, JX; Sperelakis, R, 1997
)
0.58
"Tiagabine is efficacious and well tolerated as adjunctive therapy for CPS; there is a clear dose-response relationship."( Tiagabine for complex partial seizures: a randomized, add-on, dose-response trial.
Ahmann, PA; Leppik, IE; Rowan, AJ; Schachter, SC; Shu, V; Sommerville, KW; Uthman, BM, 1998
)
3.19
"TGB pharmacokinetics and tolerability were independent of renal function; therefore, dosage adjustment is unnecessary for epilepsy patients with renal impairment."( Effect of renal impairment on the pharmacokinetics and tolerability of tiagabine.
Cato, A; El-Shourbagy, T; Gustavson, LE; Kelly, EA; Qian, J, 1998
)
0.53
" Following a 7-day washout period, volunteers crossed over to the other dosing regimen."( Tiagabine, a novel antiepileptic agent: lack of pharmacokinetic interaction with digoxin.
Jansen, JA; Jonkman, JH; Pedersen, PC; Snel, S; van Heiningen, PN, 1998
)
1.74
"To provide a comprehensive review of tiagabine, including its pharmacology, toxicology, pharmacokinetics, drug interactions, efficacy, adverse effects, and dosing recommendations."( Tiagabine: a novel antiepileptic drug.
Luer, MS; Rhoney, DH, 1998
)
2.02
" All three patients improved during adjunctive low dosage tiagabine treatment and no untoward side effects were noted."( Adjunctive tiagabine treatment of psychiatric disorders: three cases.
Kaufman, KR, 1998
)
0.93
" Twelve adult patients with seizures controlled by an individualized fixed dosage of antiepilepsy medication (carbamazepine or phenytoin) participated in each study."( Lack of pharmacokinetic drug interactions between tiagabine and carbamazepine or phenytoin.
Boellner, SW; Cao, GX; Cato, A; Guenther, HJ; Gustavson, LE; Qian, JX; Sommerville, KW, 1998
)
0.55
" Twelve adult patients with seizures controlled by an individualized fixed dosage of valproate participated in the study."( Lack of a clinically significant pharmacokinetic drug interaction between tiagabine and valproate.
Boellner, SW; Granneman, GR; Guenther, HJ; Gustavson, LE; Sommerville, KW; Witt, GF, 1998
)
0.53
" Administration of lorazepam and immediate reduction in TGB dosage was followed by complete clinical and electroencephalographic remission."( Tiagabine-induced absence status in idiopathic generalized epilepsy.
Hamer, HM; Knake, S; Oertel, WH; Rosenow, F; Schomburg, U, 1999
)
1.75
" Conversion to TGB monotherapy can be achieved in patients with medically refractory epilepsy, although additional controlled studies are needed to confirm the efficacy of TGB as monotherapy and to establish the effective dosage range."( Tiagabine.
Schachter, SC, 1999
)
1.75
" It also appears that rapid dosage increases for antimanic treatment can cause potentially severe side effects."( Tiagabine appears not to be efficacious in the treatment of acute mania.
Amann, B; Erfurth, A; Grunze, H; Marcuse, A; Normann, C; Walden, J, 1999
)
1.75
" The first was a dose-response study employing doses of TGB-HCl of 16, 32 or 56 mg/day."( Review of controlled trials of gabitril (tiagabine): a clinician's viewpoint.
Loiseau, P, 1999
)
0.57
" Although patients who have medically refractory epilepsy can be converted to TGB monotherapy, more controlled studies are necessary to confirm the efficacy of TGB as monotherapy and to determine the effective dosage range."( A review of the antiepileptic drug tiagabine.
Schachter, SC,
)
0.41
" In two cases, tiagabine was withdrawn, whereas it was continued at a lower dosage in one case."( Provocation of non-convulsive status epilepticus by tiagabine in three adolescent patients.
Balslev, T; Buchholt, J; Uldall, P, 2000
)
0.91
" Twenty-three patients with localisation-related epilepsy syndromes were included and 17 of these patients entered the fourth dosing period."( Tiagabine adjunctive therapy in children with refractory epilepsy: a single-blind dose escalating study.
Bulteau, C; Dulac, O; Lyby, K; Pedersen, SA; Uldall, P, 2000
)
1.75
" GTCSs were suppressed by TGB in the adult and 25-day-old rats, and a U-shaped dose-response curve was outlined in these two groups."( Two different anticonvulsant actions of tiagabine in developing rats.
Haugvicová, R; Kubová, H; Mares, P; Skutová, M; Suchomelová, L, 2000
)
0.57
" A reduction in tiagabine dosage to 15 mg/day led to complete regression of the behavioral and affective changes and to disappearance of the subcontinuous EEG discharges."( Frontal nonconvulsive status epilepticus associated with high-dose tiagabine therapy in a child with familial bilateral perisylvian polymicrogyria.
Balottin, U; Borgatti, R; Donati, G; Perucca, E; Piccinelli, P; Tofani, A, 2000
)
0.89
" These results confirm that a slow titration and appropriate adjustment of dosing are essential conditions to ensure optimal use of tiagabine."( Comparison of twice- and three times daily tiagabine for the adjunctive treatment of partial seizures in refractory patients with epilepsy: an open label, randomised, parallel-group study.
Beaussart, M; Biraben, A; Josien, E; Pestre, M; Renault-Djouadi, J; Savet, JF; Schaff, JL; Sevestre, M; Tourniaire, D, 2001
)
0.78
" TGB is sensitive to enzyme induction: when coprescribed with enzyme-inducing AEDs, its half-life is shortened to 2-3 h, whereas the daily dosage has to be increased into the upper range."( Tiagabine in clinical practice.
Genton, P; Guerrini, R; Perucca, E, 2001
)
1.75
" TGB was added to previous AEDs, at dosage of 20-60 mg per die."( Tiagabine in glial tumors.
Bilo, L; Boccella, P; Nocerino, C; Striano, P; Striano, S, 2002
)
1.76
" We report three cases where elevation of tiagabine dosage was followed by electroclinical features, or electroencephalographic features without clinical signs, of non-convulsive status epilepticus."( Tiagabine-related non-convulsive status epilepticus in partial epilepsy: three case reports and a review of the literature.
Dziewas, R; Kellinghaus, C; Lüdemann, P, 2002
)
2.02
" The classic AEDs had numerous problems, ranging from inconvenient dosing schedules to frequent side effects due to active metabolites and common drug interactions; newer agents have been developed to avoid some of these pitfalls."( Pharmacokinetics of new anticonvulsants in psychiatry.
Morris, HH, 1998
)
0.3
" A dose-response relationship was also explored."( Aggravation of partial seizures by antiepileptic drugs: is there evidence from clinical trials?
Somerville, ER, 2002
)
0.31
" There was some evidence for a dose-response effect with TGB but a negative effect with TPM (aggravation less likely with increasing dose)."( Aggravation of partial seizures by antiepileptic drugs: is there evidence from clinical trials?
Somerville, ER, 2002
)
0.31
" It is currently available in a tablet dosage form, which cannot be used in young children who are unable to swallow and given doses in milligrams per kilogram of body weight."( Stability of tiagabine in two oral liquid vehicles.
Morosco, RS; Nahata, MC, 2003
)
0.69
" Although its half-life is relatively short (6 to 8 hours), its duration of action is longer than anticipated from its pharmacokinetics in plasma, and a twice-daily dosing regimen is adequate to produce the desired response."( The ideal pharmacokinetic properties of an antiepileptic drug: how close does levetiracetam come?
Johannessen, SI; Perucca, E, 2003
)
0.32
" NCSE was developed when rapid dosage increase and high dose of TGB was given."( Non-convulsive status epilepticus associated with tiagabine therapy in children.
Skardoutsou, A; Vagiakou, EA; Voudris, KA, 2003
)
0.57
" During weeks 7 through 10, patients received the dosage determined during the titration period."( Tiagabine for the treatment of generalized anxiety disorder: a randomized, open-label, clinical trial with paroxetine as a positive control.
Rosenthal, M, 2003
)
1.76
" The mean effective daily dosage was approximately 8 mg (range, 4-12 mg/day)."( Tiagabine for posttraumatic stress disorder: a case series of 7 women.
Taylor, FB, 2003
)
1.76
"In acute anxiety treatment, very low initial dosing with gradual increases may be sufficient for anxiety effects, when compared with the higher doses of tiagabine used in epilepsy treatment."( Low-dose tiagabine effectiveness in anxiety disorders.
Rawlings, D; Schaller, JL; Thomas, J, 2004
)
0.94
" There were no significant differences between dosage regimens in the change in median seizure rates from baseline."( A randomised open-label study of tiagabine given two or three times daily in refractory epilepsy.
Arroyo, S; Boothman, BR; Brodie, MJ; Calandre, EP; Crawford, PM; Duncan, JS; Duncan, R; Forcadas, I; Nieto, M, 2005
)
0.61
" These results present a novel interpretation of synergistic inhibition of certain epileptic discharges using vigabatrin and another drug, and that for successful synergistic treatment of epilepsies carefully designed timed dosage regimens are essential."( Antiepileptic action induced by a combination of vigabatrin and tiagabine.
Fueta, Y; Kunugita, N; Schwarz, W, 2005
)
0.57
"5-5 mg/kg) produced a rightward shift of a heroin dose-response curve, while vigabatrin (75-300 mg/kg), baclofen (0."( Role of opioidergic mechanisms and GABA uptake inhibition in the heroin-induced discriminative stimulus effects in rats.
Filip, M; Krówka, T; Przewłocki, R; Solecki, W,
)
0.13
" Tiagabine was initiated at 4 mg/day and then flexibly dosed twice a day to a maximum dose of 16 mg/day."( The selective GABA reuptake inhibitor tiagabine for the treatment of generalized anxiety disorder: results of a placebo-controlled study.
Brown, C; Ondrasik, J; Pollack, MH; Rickels, K; Roy-Byrne, PP; Snyder, H; Van Ameringen, M, 2005
)
1.51
" For these older drugs it has been common practice to adjust the dosage to achieve a serum drug concentration within a predefined 'therapeutic range', representing an interval where most patients are expected to show an optimal response."( Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed?
Johannessen, SI; Tomson, T, 2006
)
0.33
"This study evaluated dose-response effects of tiagabine on sleep in adults with primary insomnia."( Tiagabine increases slow-wave sleep in a dose-dependent fashion without affecting traditional efficacy measures in adults with primary insomnia.
Jiang, J; Krystal, A; Perlis, M; Rosenthal, M; Roth, T; Walsh, JK, 2006
)
2.03
"9%) seizure frequency was reduced by more than 50% (mean FBM dosage 3211 mg), and 13 patients (31."( [Treatment of epilepsy with third-line antiepileptic drugs: felbamate, tiagabine, and sulthiame].
Bauer, J; Chahem, J, 2007
)
0.57
"Tiagabine, in excess dosing scenarios, has been rarely documented to cause status epilepticus."( Status epilepticus due to tiagabine ingestion.
Benigno, J; Dubow, JS; Fisher, M; Leikin, JB,
)
1.87
" The results indicated that both drugs produced clear anticonvulsant effects against PTZ-induced clonic seizures in mice, but that their dose-response relationship curves (DRRCs) were not parallel, consequently necessitating the isobolographic analysis for non-parallel DRRCs."( Interactions of tiagabine with ethosuximide in the mouse pentylenetetrazole-induced seizure model: an isobolographic analysis for non-parallel dose-response relationship curves.
Luszczki, JJ, 2008
)
0.69
" Log-probit analysis was used to evaluate dose-response effects and calculate the ED(50) values for gabapentin, tiagabine, and their combination at the fixed-ratio of 1:1 in the phases I and II of the formalin test in mice."( Synergistic interaction of gabapentin with tiagabine in the formalin test in mice: an isobolographic analysis.
Czuczwar, M; Czuczwar, SJ; Kolacz, A; Luszczki, JJ; Przesmycki, K, 2009
)
0.83
"To characterize the interaction between tiagabine (TGB) and valproate (VPA)--two antiepileptic drugs in the mouse pentylenetetrazole (PTZ)-induced clonic seizure model, type I isobolographic analysis for non-parallel dose-response relationship curves (DRRCs) was used."( Interaction of tiagabine with valproate in the mouse pentylenetetrazole-induced seizure model: an isobolographic analysis for non-parallel dose-response relationship curves.
Krzyzanowski, M; Luszczki, JJ; Swiader, MJ, 2009
)
0.97
" Linear regression analysis was used to evaluate the dose-response relationships between logarithms of antiepileptic drug doses and their resultant maximum possible antinociceptive effects in the mouse hot-plate test."( Synergistic interaction of gabapentin with tiagabine in the hot-plate test in mice: an isobolographic analysis.
Czuczwar, M; Czuczwar, SJ; Kołacz, A; Luszczki, JJ; Przesmycki, K; Wojda, E,
)
0.39
" The small number of subjects limits the generality of the findings, and previous studies with tiagabine are limited to acute dosing and case report investigations."( Chronic tiagabine administration and aggressive responding in individuals with a history of substance abuse and antisocial behavior.
Alcorn, JL; Gowin, JL; Green, CE; Lane, SD; Moeller, FG; Swann, AC, 2012
)
1.03
"This was an open-label three-week polysomnographic (PSG) study of nightly treatment with tiagabine dosing from 2-12 mg including 20 adults with PTSD with ≥30 min of self-reported and PSG wake time after sleep onset (WASO)."( The sleep effects of tiagabine on the first night of treatment predict post-traumatic stress disorder response at three weeks.
Connor, KM; Davidson, JR; Krystal, AD; Zhang, W, 2014
)
0.94
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
GABA reuptake inhibitorA compound that inhibits the re-uptake of the neurotransmitter GABA from the synapse into the pre-synaptic neuron, so increasing the extracellular concentrations of the neurotransmitter and hence increasing neurotransmission.
anticonvulsantA drug used to prevent seizures or reduce their severity.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
piperidinemonocarboxylic acidAny member of the class of piperidines in which one of the carbons of the piperidine ring is substituted by a carboxy group.
beta-amino acidA non-proteinogenic amino acid in which the amino group is located on the carbon atom at the position beta to the carboxy group.
thiophenesCompounds containing at least one thiophene ring.
tertiary amino compoundA compound formally derived from ammonia by replacing three hydrogen atoms by organyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (10)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency11.42390.005612.367736.1254AID624032
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Sodium- and chloride-dependent GABA transporter 1Rattus norvegicus (Norway rat)IC50 (µMol)2.21070.00132.22068.3000AID1200481; AID242571; AID242581; AID242582; AID242583
Sodium- and chloride-dependent GABA transporter 1Homo sapiens (human)IC50 (µMol)0.22130.01013.090310.0000AID1192145; AID1573623; AID205303; AID258716
Sodium- and chloride-dependent GABA transporter 1Homo sapiens (human)Ki0.03240.01700.03240.0479AID1192147; AID550890
Sodium- and chloride-dependent GABA transporter 2Rattus norvegicus (Norway rat)IC50 (µMol)1,410.00000.00321.79008.3000AID205447
Sodium- and chloride-dependent GABA transporter 1Mus musculus (house mouse)IC50 (µMol)0.19680.03712.19228.5114AID1192137; AID1195448; AID1337564; AID1498417; AID1505655; AID1544944; AID1573606; AID1615004; AID1778993; AID1779017; AID1859410; AID370903; AID454709; AID722623; AID728636; AID749115; AID764602
Sodium- and chloride-dependent GABA transporter 1Mus musculus (house mouse)Ki0.03830.02750.05310.1862AID1192148; AID1285824; AID1498406; AID1544946; AID1573604; AID1602664; AID1615003; AID1859411; AID764600
Sodium- and chloride-dependent GABA transporter 2Mus musculus (house mouse)IC50 (µMol)300.00001.41255.26838.1283AID1195450; AID728635
Sodium- and chloride-dependent GABA transporter 3Mus musculus (house mouse)IC50 (µMol)800.00001.54883.67618.1283AID1195451; AID728633
Sodium- and chloride-dependent betaine transporterMus musculus (house mouse)IC50 (µMol)150.13500.18003.188010.0000AID1195449; AID728634; AID728637; AID728638
Sodium- and chloride-dependent betaine transporterHomo sapiens (human)IC50 (µMol)1,670.00000.85116.052136.0000AID205304
Sodium- and chloride-dependent GABA transporter 3Homo sapiens (human)IC50 (µMol)917.00001.00004.13318.9200AID72446
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Sodium- and chloride-dependent GABA transporter 1Homo sapiens (human)Kd0.09360.04050.09360.1468AID1573615; AID1573617
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Sodium- and chloride-dependent GABA transporter 1Homo sapiens (human)INH0.07000.04000.12330.2600AID774377
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (28)

Processvia Protein(s)Taxonomy
memorySodium- and chloride-dependent GABA transporter 1Homo sapiens (human)
associative learningSodium- and chloride-dependent GABA transporter 1Homo sapiens (human)
synapse organizationSodium- and chloride-dependent GABA transporter 1Homo sapiens (human)
chemical synaptic transmissionSodium- and chloride-dependent GABA transporter 1Homo sapiens (human)
response to toxic substanceSodium- and chloride-dependent GABA transporter 1Homo sapiens (human)
response to sucroseSodium- and chloride-dependent GABA transporter 1Homo sapiens (human)
response to inorganic substanceSodium- and chloride-dependent GABA transporter 1Homo sapiens (human)
response to lead ionSodium- and chloride-dependent GABA transporter 1Homo sapiens (human)
positive regulation of gamma-aminobutyric acid secretionSodium- and chloride-dependent GABA transporter 1Homo sapiens (human)
response to purine-containing compoundSodium- and chloride-dependent GABA transporter 1Homo sapiens (human)
negative regulation of synaptic transmission, GABAergicSodium- and chloride-dependent GABA transporter 1Homo sapiens (human)
response to estradiolSodium- and chloride-dependent GABA transporter 1Homo sapiens (human)
response to cocaineSodium- and chloride-dependent GABA transporter 1Homo sapiens (human)
response to calcium ionSodium- and chloride-dependent GABA transporter 1Homo sapiens (human)
gamma-aminobutyric acid reuptakeSodium- and chloride-dependent GABA transporter 1Homo sapiens (human)
gamma-aminobutyric acid importSodium- and chloride-dependent GABA transporter 1Homo sapiens (human)
inorganic anion import across plasma membraneSodium- and chloride-dependent GABA transporter 1Homo sapiens (human)
sodium ion import across plasma membraneSodium- and chloride-dependent GABA transporter 1Homo sapiens (human)
transport across blood-brain barrierSodium- and chloride-dependent GABA transporter 1Homo sapiens (human)
chloride transmembrane transportSodium- and chloride-dependent GABA transporter 1Homo sapiens (human)
sodium ion transmembrane transportSodium- and chloride-dependent GABA transporter 1Homo sapiens (human)
amino acid transportSodium- and chloride-dependent GABA transporter 1Homo sapiens (human)
amino acid transmembrane transportSodium- and chloride-dependent betaine transporterHomo sapiens (human)
amino acid transportSodium- and chloride-dependent betaine transporterHomo sapiens (human)
monocarboxylic acid transportSodium- and chloride-dependent betaine transporterHomo sapiens (human)
gamma-aminobutyric acid transportSodium- and chloride-dependent betaine transporterHomo sapiens (human)
glycine betaine transportSodium- and chloride-dependent betaine transporterHomo sapiens (human)
gamma-aminobutyric acid reuptakeSodium- and chloride-dependent betaine transporterHomo sapiens (human)
sodium ion transmembrane transportSodium- and chloride-dependent betaine transporterHomo sapiens (human)
amino acid transmembrane transportSodium- and chloride-dependent GABA transporter 3Homo sapiens (human)
response to xenobiotic stimulusSodium- and chloride-dependent GABA transporter 3Homo sapiens (human)
monocarboxylic acid transportSodium- and chloride-dependent GABA transporter 3Homo sapiens (human)
taurine transmembrane transportSodium- and chloride-dependent GABA transporter 3Homo sapiens (human)
gamma-aminobutyric acid reuptakeSodium- and chloride-dependent GABA transporter 3Homo sapiens (human)
sodium ion transmembrane transportSodium- and chloride-dependent GABA transporter 3Homo sapiens (human)
amino acid transportSodium- and chloride-dependent GABA transporter 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
gamma-aminobutyric acid:sodium:chloride symporter activitySodium- and chloride-dependent GABA transporter 1Homo sapiens (human)
protein bindingSodium- and chloride-dependent GABA transporter 1Homo sapiens (human)
gamma-aminobutyric acid transmembrane transporter activitySodium- and chloride-dependent GABA transporter 1Homo sapiens (human)
sodium:chloride symporter activitySodium- and chloride-dependent GABA transporter 1Homo sapiens (human)
identical protein bindingSodium- and chloride-dependent GABA transporter 1Homo sapiens (human)
metal ion bindingSodium- and chloride-dependent GABA transporter 1Homo sapiens (human)
gamma-aminobutyric acid:sodium:chloride symporter activitySodium- and chloride-dependent betaine transporterHomo sapiens (human)
protein bindingSodium- and chloride-dependent betaine transporterHomo sapiens (human)
monocarboxylic acid transmembrane transporter activitySodium- and chloride-dependent betaine transporterHomo sapiens (human)
amino acid transmembrane transporter activitySodium- and chloride-dependent betaine transporterHomo sapiens (human)
gamma-aminobutyric acid:sodium:chloride symporter activitySodium- and chloride-dependent GABA transporter 3Homo sapiens (human)
taurine:sodium symporter activitySodium- and chloride-dependent GABA transporter 3Homo sapiens (human)
monocarboxylic acid transmembrane transporter activitySodium- and chloride-dependent GABA transporter 3Homo sapiens (human)
amino acid bindingSodium- and chloride-dependent GABA transporter 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (11)

Processvia Protein(s)Taxonomy
plasma membraneSodium- and chloride-dependent GABA transporter 1Homo sapiens (human)
plasma membraneSodium- and chloride-dependent GABA transporter 1Homo sapiens (human)
membraneSodium- and chloride-dependent GABA transporter 1Homo sapiens (human)
axonSodium- and chloride-dependent GABA transporter 1Homo sapiens (human)
presynaptic membraneSodium- and chloride-dependent GABA transporter 1Homo sapiens (human)
neuronal cell bodySodium- and chloride-dependent GABA transporter 1Homo sapiens (human)
postsynaptic membraneSodium- and chloride-dependent GABA transporter 1Homo sapiens (human)
GABA-ergic synapseSodium- and chloride-dependent GABA transporter 1Homo sapiens (human)
axonSodium- and chloride-dependent GABA transporter 1Homo sapiens (human)
cell surfaceSodium- and chloride-dependent GABA transporter 1Homo sapiens (human)
plasma membraneSodium- and chloride-dependent betaine transporterHomo sapiens (human)
membraneSodium- and chloride-dependent betaine transporterHomo sapiens (human)
basolateral plasma membraneSodium- and chloride-dependent betaine transporterHomo sapiens (human)
presynapseSodium- and chloride-dependent betaine transporterHomo sapiens (human)
cell projectionSodium- and chloride-dependent betaine transporterHomo sapiens (human)
plasma membraneSodium- and chloride-dependent betaine transporterHomo sapiens (human)
plasma membraneSodium- and chloride-dependent GABA transporter 3Homo sapiens (human)
membraneSodium- and chloride-dependent GABA transporter 3Homo sapiens (human)
presynaptic membraneSodium- and chloride-dependent GABA transporter 3Homo sapiens (human)
postsynaptic membraneSodium- and chloride-dependent GABA transporter 3Homo sapiens (human)
GABA-ergic synapseSodium- and chloride-dependent GABA transporter 3Homo sapiens (human)
plasma membraneSodium- and chloride-dependent GABA transporter 3Homo sapiens (human)
cell projectionSodium- and chloride-dependent GABA transporter 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (135)

Assay IDTitleYearJournalArticle
AID749109Inhibition of mouse GAT4 expressed in HEK cells assessed as remaining [3H]-GABA uptake at 100 uM after 25 mins by liquid scintillation counting analysis relative to control2013Bioorganic & medicinal chemistry, Jun-01, Volume: 21, Issue:11
Synthesis and evaluation of N-substituted nipecotic acid derivatives with an unsymmetrical bis-aromatic residue attached to a vinyl ether spacer as potential GABA uptake inhibitors.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1192137Inhibition of mouse GAT1 expressed in HEK293 cells by [3H]GABA uptake assay2015Bioorganic & medicinal chemistry, Mar-15, Volume: 23, Issue:6
Design, synthesis and SAR studies of GABA uptake inhibitors derived from 2-substituted pyrrolidine-2-yl-acetic acids.
AID1498418Inhibition of mouse GAT2 expressed in HEK293 cells assessed as decrease in [3H]GABA uptake at 100 uM relative to control2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Synthesis and biological evaluation of novel N-substituted nipecotic acid derivatives with an alkyne spacer as GABA uptake inhibitors.
AID227701Anticonvulsant activity; NC denotes that compound is not classified2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Topological virtual screening: a way to find new anticonvulsant drugs from chemical diversity.
AID1573626Mixed-type inhibition of human GAT1 expressed in COS cells assessed as reduction in [2H6]GABA uptake by measuring [2H6]GABA Vmax at 300 nM preincubated for 25 mins followed by [3H]GABA addition and measured after 4 mins by liquid scintillation counting me2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Novel Allosteric Ligands of γ-Aminobutyric Acid Transporter 1 (GAT1) by MS Based Screening of Pseudostatic Hydrazone Libraries.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID242583H-bonding interaction between amino acid residue (Tyr-140) of Sodium- and chloride-dependent GABA transporter 1TM3 and compound was determined2004Journal of medicinal chemistry, Nov-04, Volume: 47, Issue:23
Novel secoergoline derivatives inhibit both GABA and glutamate uptake in rat brain homogenates: synthesis, in vitro pharmacology, and modeling.
AID1573606Inhibition of mouse GAT1 expressed in HEK293 cells assessed as reduction in [3H]GABA uptake preincubated for 25 mins followed by [3H]GABA addition and measured after 4 mins by liquid scintillation counting method2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Novel Allosteric Ligands of γ-Aminobutyric Acid Transporter 1 (GAT1) by MS Based Screening of Pseudostatic Hydrazone Libraries.
AID370903Inhibition of [3H]GABA uptake at mouse GAT1 expressed in HEK cells2008European journal of medicinal chemistry, Nov, Volume: 43, Issue:11
Synthesis and biological evaluation of aminomethylphenol derivatives as inhibitors of the murine GABA transporters mGAT1-mGAT4.
AID1498417Inhibition of mouse GAT1 expressed in HEK293 cells assessed as decrease in [3H]GABA uptake2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Synthesis and biological evaluation of novel N-substituted nipecotic acid derivatives with an alkyne spacer as GABA uptake inhibitors.
AID205304Inhibition of human GABA transporter (hBGT-1) activity.1994Journal of medicinal chemistry, Jul-22, Volume: 37, Issue:15
Design, synthesis and evaluation of substituted triarylnipecotic acid derivatives as GABA uptake inhibitors: identification of a ligand with moderate affinity and selectivity for the cloned human GABA transporter GAT-3.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1192156Inhibition of mouse GAT2 expressed in HEK293 cells assessed as remaining [3H]GABA uptake at 100 uM by [3H]GABA uptake assay2015Bioorganic & medicinal chemistry, Mar-15, Volume: 23, Issue:6
Design, synthesis and SAR studies of GABA uptake inhibitors derived from 2-substituted pyrrolidine-2-yl-acetic acids.
AID1192158Inhibition of mouse GAT4 expressed in HEK293 cells assessed as remaining [3H]GABA uptake at 100 uM by [3H]GABA uptake assay2015Bioorganic & medicinal chemistry, Mar-15, Volume: 23, Issue:6
Design, synthesis and SAR studies of GABA uptake inhibitors derived from 2-substituted pyrrolidine-2-yl-acetic acids.
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1736183Inhibition of mouse GAT2 expressed in HEK293 cell line assessed as inhibition of [3H]GABA uptake at 100 uM measured after 35 mins by liquid scintillation method2020European journal of medicinal chemistry, Feb-15, Volume: 188Novel mouse GABA uptake inhibitors with enhanced inhibitory activity toward mGAT3/4 and their effect on pain threshold in mice.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID1779017Inhibition of [3H]NO711 binding to mouse GAT1 expressed in human HEK293 cell line by MS binding assay2021European journal of medicinal chemistry, Oct-05, Volume: 221Development of tricyclic N-benzyl-4-hydroxybutanamide derivatives as inhibitors of GABA transporters mGAT1-4 with anticonvulsant, antinociceptive, and antidepressant activity.
AID1337578Inhibition of mouse GAT4 expressed in HEK293 cells assessed as decrease in [3H]GABA uptake at 100 uM preincubated for 25 mins followed by [3H]GABA addition measured after 4 mins by liquid scintillation counter method2016European journal of medicinal chemistry, Nov-29, Volume: 124Synthesis and biological evaluation of a series of N-alkylated imidazole alkanoic acids as mGAT3 selective GABA uptake inhibitors.
AID1195450Inhibition of mouse mGAT3 expressed in HEK293 cells assessed as inhibition of [3H]GABA uptake after 3 mins incubation by TopCount microplate scintillation counting analysis2015Bioorganic & medicinal chemistry, May-15, Volume: 23, Issue:10
Structure activity relationship of selective GABA uptake inhibitors.
AID1505655Inhibition of mouse GAT1 assessed as reduction in GABA uptake2018Journal of medicinal chemistry, 07-26, Volume: 61, Issue:14
Development of New Photoswitchable Azobenzene Based γ-Aminobutyric Acid (GABA) Uptake Inhibitors with Distinctly Enhanced Potency upon Photoactivation.
AID1573625Mixed-type inhibition of human GAT1 expressed in COS cells assessed as reduction in [2H6]GABA uptake by measuring [2H6]GABA Vmax at 100 nM preincubated for 25 mins followed by [3H]GABA addition and measured after 4 mins by liquid scintillation counting me2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Novel Allosteric Ligands of γ-Aminobutyric Acid Transporter 1 (GAT1) by MS Based Screening of Pseudostatic Hydrazone Libraries.
AID258716Inhibition of GAT1 transport activity2006Bioorganic & medicinal chemistry letters, Jan-01, Volume: 16, Issue:1
Design, synthesis, and biological evaluation of the N-diarylalkenyl-piperidinecarboxylic acid derivatives as GABA uptake inhibitors (I).
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID242581H-bonding interaction between amino acid residue (Asn-137) of Sodium- and chloride-dependent GABA transporter 1TM3 and compound2004Journal of medicinal chemistry, Nov-04, Volume: 47, Issue:23
Novel secoergoline derivatives inhibit both GABA and glutamate uptake in rat brain homogenates: synthesis, in vitro pharmacology, and modeling.
AID1544944Inhibition of mouse GAT1 expressed in HEK293 cells assessed as reduction in [3H]GABA uptake preincubated for 25 mins followed by [3H]GABA addition and measured after 4 mins by liquid scintillation counting method2019Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13
Application of the concept of oxime library screening by mass spectrometry (MS) binding assays to pyrrolidine-3-carboxylic acid derivatives as potential inhibitors of γ-aminobutyric acid transporter 1 (GAT1).
AID487212Inhibition of GAT1-mediated [3H]GABA uptake in bovine brain stem2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Azetidine derivatives as novel gamma-aminobutyric acid uptake inhibitors: synthesis, biological evaluation, and structure-activity relationship.
AID749111Inhibition of mouse GAT2 expressed in HEK cells assessed as remaining [3H]-GABA uptake at 100 uM after 25 mins by liquid scintillation counting analysis relative to control2013Bioorganic & medicinal chemistry, Jun-01, Volume: 21, Issue:11
Synthesis and evaluation of N-substituted nipecotic acid derivatives with an unsymmetrical bis-aromatic residue attached to a vinyl ether spacer as potential GABA uptake inhibitors.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID476929Human intestinal absorption in po dosed human2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
AID444050Fraction unbound in human plasma2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1192157Inhibition of mouse GAT3 expressed in HEK293 cells assessed as remaining [3H]GABA uptake at 100 uM by [3H]GABA uptake assay2015Bioorganic & medicinal chemistry, Mar-15, Volume: 23, Issue:6
Design, synthesis and SAR studies of GABA uptake inhibitors derived from 2-substituted pyrrolidine-2-yl-acetic acids.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1602655Inhibition of GAT-1 in rat brain homogenate assessed as decrease in [3H]GABA uptake preincubated for 8 mins followed by [3H]GABA addition and measured after 8 mins by scintillation counting analysis2019Bioorganic & medicinal chemistry, 04-01, Volume: 27, Issue:7
Screening oxime libraries by means of mass spectrometry (MS) binding assays: Identification of new highly potent inhibitors to optimized inhibitors γ-aminobutyric acid transporter 1.
AID728634Inhibition of [3H]GABA uptake at mouse GAT2 expressed in HEK293 cells after 3 mins by scintillation counting analysis2013Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5
Selective mGAT2 (BGT-1) GABA uptake inhibitors: design, synthesis, and pharmacological characterization.
AID242582H-bonding interaction between amino acid residue (Ser-133) of Sodium- and chloride-dependent GABA transporter 1TM3 and compound was determined2004Journal of medicinal chemistry, Nov-04, Volume: 47, Issue:23
Novel secoergoline derivatives inhibit both GABA and glutamate uptake in rat brain homogenates: synthesis, in vitro pharmacology, and modeling.
AID1859411Binding affinity to mouse GAT-1 expressed in human HEK293 cells assessed as inhibition constant in presence of NO711 marker by competitive binding assay2022European journal of medicinal chemistry, Apr-15, Volume: 234Nipecotic acid as potential lead molecule for the development of GABA uptake inhibitors; structural insights and design strategies.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID728638Inhibition of [3H]GABA uptake at GAT2 in mouse astrocytes after 3 mins by scintillation counting analysis2013Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5
Selective mGAT2 (BGT-1) GABA uptake inhibitors: design, synthesis, and pharmacological characterization.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1736184Inhibition of mouse GAT3 expressed in HEK293 cell line assessed as inhibition of [3H]GABA uptake at 100 uM measured after 35 mins by liquid scintillation method2020European journal of medicinal chemistry, Feb-15, Volume: 188Novel mouse GABA uptake inhibitors with enhanced inhibitory activity toward mGAT3/4 and their effect on pain threshold in mice.
AID550890Displacement of [3H]Tiagabine from human recombinant GAT1 expressed in HEK293 cells by equilibrium binding assay2011Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1
Stereospecific synthesis and structure-activity relationships of unsymmetrical 4,4-diphenylbut-3-enyl derivatives of nipecotic acid as GAT-1 inhibitors.
AID1573627Mixed-type inhibition of human GAT1 expressed in COS cells assessed as reduction in [2H6]GABA uptake by measuring [2H6]GABA Km(app) at 300 nM preincubated for 25 mins followed by [3H]GABA addition and measured after 4 mins by liquid scintillation counting2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Novel Allosteric Ligands of γ-Aminobutyric Acid Transporter 1 (GAT1) by MS Based Screening of Pseudostatic Hydrazone Libraries.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID311524Oral bioavailability in human2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Hologram QSAR model for the prediction of human oral bioavailability.
AID1779009Antidepressant activity in Albino Swiss (CD-1) mouse assessed as reduction in immobility time at 8 mg/kg, ip measured for last 4 mins of 6 mins test by forced swim test relative to control2021European journal of medicinal chemistry, Oct-05, Volume: 221Development of tricyclic N-benzyl-4-hydroxybutanamide derivatives as inhibitors of GABA transporters mGAT1-4 with anticonvulsant, antinociceptive, and antidepressant activity.
AID1544946Inhibition of NO711 binding to mouse GAT1 expressed in HEK293 cell membranes assessed as reduction in NO711 binding at incubated for 4 hrs in presence of NO711 by LC-ESI-MS/MS analysis relative to control2019Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13
Application of the concept of oxime library screening by mass spectrometry (MS) binding assays to pyrrolidine-3-carboxylic acid derivatives as potential inhibitors of γ-aminobutyric acid transporter 1 (GAT1).
AID1285824Displacement of NO 711 from mouse GAT1 expressed in HEK293 cell membranes after 40 mins by LC-ESI-MS-MS-based MS binding assay2016Bioorganic & medicinal chemistry, May-01, Volume: 24, Issue:9
Synthesis of 4-substituted nipecotic acid derivatives and their evaluation as potential GABA uptake inhibitors.
AID1337577Inhibition of mouse GAT3 expressed in HEK293 cells assessed as decrease in [3H]GABA uptake at 100 uM preincubated for 25 mins followed by [3H]GABA addition measured after 4 mins by liquid scintillation counter method2016European journal of medicinal chemistry, Nov-29, Volume: 124Synthesis and biological evaluation of a series of N-alkylated imidazole alkanoic acids as mGAT3 selective GABA uptake inhibitors.
AID205303Inhibitory activity against human GABA transporter-1 (hGAT1)1994Journal of medicinal chemistry, Jul-22, Volume: 37, Issue:15
Design, synthesis and evaluation of substituted triarylnipecotic acid derivatives as GABA uptake inhibitors: identification of a ligand with moderate affinity and selectivity for the cloned human GABA transporter GAT-3.
AID728635Inhibition of [3H]GABA uptake at mouse GAT3 expressed in HEK293 cells after 3 mins by scintillation counting analysis2013Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5
Selective mGAT2 (BGT-1) GABA uptake inhibitors: design, synthesis, and pharmacological characterization.
AID1615011Inhibition of mouse GAT4 expressed in HEK293 cells assessed as remaining [3H]GABA uptake at 100 uM preincubated for 25 mins followed by [3H]GABA addition and measured after 4 mins by liquid scintillation counting method relative to control2019Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5
Synthesis and biological evaluation of novel N-substituted nipecotic acid derivatives with a cis-alkene spacer as GABA uptake inhibitors.
AID370910Inhibition of [3H]GABA uptake at mouse GAT4 expressed in HEK cells assessed as remaining [3H]GABA uptake at 100 uM relative to control2008European journal of medicinal chemistry, Nov, Volume: 43, Issue:11
Synthesis and biological evaluation of aminomethylphenol derivatives as inhibitors of the murine GABA transporters mGAT1-mGAT4.
AID1573617Competitive inhibition of human GAT1 expressed in COS cells assessed as reduction in [2H6]GABA uptake by measuring [2H6]GABA Kd(app) at 1 uM preincubated for 25 mins followed by [2H6]GABA addition and measured after 4 mins by liquid scintillation counting2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Novel Allosteric Ligands of γ-Aminobutyric Acid Transporter 1 (GAT1) by MS Based Screening of Pseudostatic Hydrazone Libraries.
AID1337564Inhibition of mouse GAT1 expressed in HEK293 cells assessed as decrease in [3H]GABA uptake preincubated for 25 mins followed by [3H]GABA addition measured after 4 mins by liquid scintillation counter method2016European journal of medicinal chemistry, Nov-29, Volume: 124Synthesis and biological evaluation of a series of N-alkylated imidazole alkanoic acids as mGAT3 selective GABA uptake inhibitors.
AID728631Selectivity ratio of IC50 for mouse GAT2 to IC50 for mouse GAT12013Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5
Selective mGAT2 (BGT-1) GABA uptake inhibitors: design, synthesis, and pharmacological characterization.
AID242571H-bonding interaction between amino acid residue (Thr-89) of Sodium- and chloride-dependent GABA transporter 1TM2 and compound2004Journal of medicinal chemistry, Nov-04, Volume: 47, Issue:23
Novel secoergoline derivatives inhibit both GABA and glutamate uptake in rat brain homogenates: synthesis, in vitro pharmacology, and modeling.
AID1615003Displacement of NO711 from mouse GAT1 expressed in stable HEK293 cell membranes preincubated for 10 mins followed by NO711 addition and measured after 40 mins by LC-ESI-MS/MS analysis2019Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5
Synthesis and biological evaluation of novel N-substituted nipecotic acid derivatives with a cis-alkene spacer as GABA uptake inhibitors.
AID1195449Inhibition of mouse mGAT2 expressed in HEK293 cells assessed as inhibition of [3H]GABA uptake after 3 mins incubation by TopCount microplate scintillation counting analysis2015Bioorganic & medicinal chemistry, May-15, Volume: 23, Issue:10
Structure activity relationship of selective GABA uptake inhibitors.
AID1195451Inhibition of mouse mGAT4 expressed in HEK293 cells assessed as inhibition of [3H]GABA uptake after 3 mins incubation by TopCount microplate scintillation counting analysis2015Bioorganic & medicinal chemistry, May-15, Volume: 23, Issue:10
Structure activity relationship of selective GABA uptake inhibitors.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1200481Inhibition of rat GAT1 expressed in HEK293 cells assessed as inhibition of [3H]GABA uptake by liquid scintillation counting2015Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5
A binding mode hypothesis of tiagabine confirms liothyronine effect on γ-aminobutyric acid transporter 1 (GAT1).
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID764600Binding affinity to mouse GAT1 stably transfected in HEK293 cells by NO-711 binding assay2013Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17
2-Substituted 4-hydroxybutanamides as potential inhibitors of γ-aminobutyric acid transporters mGAT1-mGAT4: synthesis and biological evaluation.
AID1195448Inhibition of mouse mGAT1 expressed in HEK293 cells assessed as inhibition of [3H]GABA uptake after 3 mins incubation by TopCount microplate scintillation counting analysis2015Bioorganic & medicinal chemistry, May-15, Volume: 23, Issue:10
Structure activity relationship of selective GABA uptake inhibitors.
AID722623Inhibition of [3H]GABA uptake at mouse GAT1 expressed in HEK293 cells after 25 mins by scintillation counting analysis2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Focused pseudostatic hydrazone libraries screened by mass spectrometry binding assay: optimizing affinities toward γ-aminobutyric acid transporter 1.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1192148Binding affinity to mouse GAT1 expressed in HEK293 cells using NO71156 as unlabelled marker by LC-ESI-MS-MS based competitive MS binding assay2015Bioorganic & medicinal chemistry, Mar-15, Volume: 23, Issue:6
Design, synthesis and SAR studies of GABA uptake inhibitors derived from 2-substituted pyrrolidine-2-yl-acetic acids.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1573773Inhibition of human GAT3 expressed in COS7 cells assessed as reduction in [2H6]GABA uptake by measuring remaining [2H6]GABA uptake level at 250 uM preincubated for 25 mins followed by [2H6]GABA addition and measured after 6 mins by LC-MS/MS analysis2019Bioorganic & medicinal chemistry, 01-01, Volume: 27, Issue:1
Generation and screening of pseudostatic hydrazone libraries derived from 5-substituted nipecotic acid derivatives at the GABA transporter mGAT4.
AID1778993Inhibition of mouse GAT1 expressed in human HEK293 cell line assessed as inhibition of [3H]GABA uptake measured after 40 mins by LC-ESI-MS/MS analysis2021European journal of medicinal chemistry, Oct-05, Volume: 221Development of tricyclic N-benzyl-4-hydroxybutanamide derivatives as inhibitors of GABA transporters mGAT1-4 with anticonvulsant, antinociceptive, and antidepressant activity.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID749115Inhibition of mouse GAT1 expressed in HEK cells assessed as inhibition of [3H]-GABA uptake after 25 mins by liquid scintillation counting analysis2013Bioorganic & medicinal chemistry, Jun-01, Volume: 21, Issue:11
Synthesis and evaluation of N-substituted nipecotic acid derivatives with an unsymmetrical bis-aromatic residue attached to a vinyl ether spacer as potential GABA uptake inhibitors.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1573616Competitive inhibition of human GAT1 expressed in COS cells assessed as reduction in [2H6]GABA uptake by measuring [2H6]GABA Bmax at 1 uM preincubated for 25 mins followed by [2H6]GABA addition and measured after 4 mins by liquid scintillation counting me2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Novel Allosteric Ligands of γ-Aminobutyric Acid Transporter 1 (GAT1) by MS Based Screening of Pseudostatic Hydrazone Libraries.
AID764598Inhibition of mouse GAT2-mediated [3H]GABA uptake stably transfected in HEK293 cells assessed as residual uptake at 100 uM relative to control2013Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17
2-Substituted 4-hydroxybutanamides as potential inhibitors of γ-aminobutyric acid transporters mGAT1-mGAT4: synthesis and biological evaluation.
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1573613Inhibition of human GAT1 expressed in HEK293 cells assessed as reduction in [3H]GABA uptake preincubated for 25 mins followed by [3H]GABA addition and measured after 4 mins by liquid scintillation counting method2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Novel Allosteric Ligands of γ-Aminobutyric Acid Transporter 1 (GAT1) by MS Based Screening of Pseudostatic Hydrazone Libraries.
AID1859410Inhibition of mouse GAT-1 expressed in human HEK293 cells assessed as inhibition of [3H]GABA uptake2022European journal of medicinal chemistry, Apr-15, Volume: 234Nipecotic acid as potential lead molecule for the development of GABA uptake inhibitors; structural insights and design strategies.
AID1573614Competitive inhibition of human GAT1 expressed in COS cells assessed as reduction in [2H6]GABA uptake by measuring [2H6]GABA Bmax at 100 nM preincubated for 25 mins followed by [2H6]GABA addition and measured after 4 mins by liquid scintillation counting 2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Novel Allosteric Ligands of γ-Aminobutyric Acid Transporter 1 (GAT1) by MS Based Screening of Pseudostatic Hydrazone Libraries.
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID728633Inhibition of [3H]GABA uptake at mouse GAT4 expressed in HEK293 cells after 3 mins by scintillation counting analysis2013Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5
Selective mGAT2 (BGT-1) GABA uptake inhibitors: design, synthesis, and pharmacological characterization.
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID764602Inhibition of mouse GAT1-mediated [3H]GABA uptake stably transfected in HEK293 cells2013Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17
2-Substituted 4-hydroxybutanamides as potential inhibitors of γ-aminobutyric acid transporters mGAT1-mGAT4: synthesis and biological evaluation.
AID728637Inhibition of [3H]GABA uptake at GAT2 in mouse neurons after 3 mins by scintillation counting analysis2013Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5
Selective mGAT2 (BGT-1) GABA uptake inhibitors: design, synthesis, and pharmacological characterization.
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID72446Inhibitory activity against human sodium and chloride dependent GABA transporter 31994Journal of medicinal chemistry, Jul-22, Volume: 37, Issue:15
Design, synthesis and evaluation of substituted triarylnipecotic acid derivatives as GABA uptake inhibitors: identification of a ligand with moderate affinity and selectivity for the cloned human GABA transporter GAT-3.
AID1779019Inhibition of mouse GAT3 expressed in human HEK293 cell line assessed as inhibition of [3H]GABA uptake at 100 uM measured after 40 mins by LC-ESI-MS/MS analysis2021European journal of medicinal chemistry, Oct-05, Volume: 221Development of tricyclic N-benzyl-4-hydroxybutanamide derivatives as inhibitors of GABA transporters mGAT1-4 with anticonvulsant, antinociceptive, and antidepressant activity.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1192147Binding affinity to human GAT1 expressed in HEK293 cells using NO71156 as unlabelled marker by LC-ESI-MS-MS based competitive MS binding assay2015Bioorganic & medicinal chemistry, Mar-15, Volume: 23, Issue:6
Design, synthesis and SAR studies of GABA uptake inhibitors derived from 2-substituted pyrrolidine-2-yl-acetic acids.
AID1498420Inhibition of mouse GAT4 expressed in HEK293 cells assessed as decrease in [3H]GABA uptake2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Synthesis and biological evaluation of novel N-substituted nipecotic acid derivatives with an alkyne spacer as GABA uptake inhibitors.
AID1573604Inhibition of NO711 binding to mouse GAT1 expressed in HEK293 cell membranes assessed as residual binding preincubated for 4 hrs followed by NO711 addition and measured after 40 mins by LC-ESI-MS/MS analysis2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Novel Allosteric Ligands of γ-Aminobutyric Acid Transporter 1 (GAT1) by MS Based Screening of Pseudostatic Hydrazone Libraries.
AID1498406Inhibition of [2H10]NO 711 binding to mouse GAT1 expressed in HEK293 cell membranes by mass spectrometric analysis2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Synthesis and biological evaluation of novel N-substituted nipecotic acid derivatives with an alkyne spacer as GABA uptake inhibitors.
AID1573624Mixed-type inhibition of human GAT1 expressed in COS cells assessed as reduction in [2H6]GABA uptake by measuring [2H6]GABA Km(app) at 100 nM preincubated for 25 mins followed by [3H]GABA addition and measured after 4 mins by liquid scintillation counting2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Novel Allosteric Ligands of γ-Aminobutyric Acid Transporter 1 (GAT1) by MS Based Screening of Pseudostatic Hydrazone Libraries.
AID1779018Inhibition of mouse GAT2 expressed in human HEK293 cell line assessed as inhibition of [3H]GABA uptake at 100 uM measured after 40 mins by LC-ESI-MS/MS analysis2021European journal of medicinal chemistry, Oct-05, Volume: 221Development of tricyclic N-benzyl-4-hydroxybutanamide derivatives as inhibitors of GABA transporters mGAT1-4 with anticonvulsant, antinociceptive, and antidepressant activity.
AID764596Inhibition of mouse GAT3-mediated [3H]GABA uptake stably transfected in HEK293 cells assessed as residual uptake at 100 uM relative to control2013Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17
2-Substituted 4-hydroxybutanamides as potential inhibitors of γ-aminobutyric acid transporters mGAT1-mGAT4: synthesis and biological evaluation.
AID1200480Inhibition of rat brain synaptosomes GAT1 assessed as inhibition of [3H]GABA uptake by liquid scintillation counting2015Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5
A binding mode hypothesis of tiagabine confirms liothyronine effect on γ-aminobutyric acid transporter 1 (GAT1).
AID1498419Inhibition of mouse GAT3 expressed in HEK293 cells assessed as decrease in [3H]GABA uptake2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Synthesis and biological evaluation of novel N-substituted nipecotic acid derivatives with an alkyne spacer as GABA uptake inhibitors.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID370909Inhibition of [3H]GABA uptake at mouse GAT3 expressed in HEK cells assessed as remaining [3H]GABA uptake at 100 uM relative to control2008European journal of medicinal chemistry, Nov, Volume: 43, Issue:11
Synthesis and biological evaluation of aminomethylphenol derivatives as inhibitors of the murine GABA transporters mGAT1-mGAT4.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID749110Inhibition of mouse GAT3 expressed in HEK cells assessed as remaining [3H]-GABA uptake at 100 uM after 25 mins by liquid scintillation counting analysis relative to control2013Bioorganic & medicinal chemistry, Jun-01, Volume: 21, Issue:11
Synthesis and evaluation of N-substituted nipecotic acid derivatives with an unsymmetrical bis-aromatic residue attached to a vinyl ether spacer as potential GABA uptake inhibitors.
AID1736185Inhibition of mouse GAT4 expressed in HEK293 cell line assessed as inhibition of [3H]GABA uptake at 100 uM measured after 35 mins by liquid scintillation method2020European journal of medicinal chemistry, Feb-15, Volume: 188Novel mouse GABA uptake inhibitors with enhanced inhibitory activity toward mGAT3/4 and their effect on pain threshold in mice.
AID205447Inhibitory activity against rat GABA transporter-2 (rGAT2)1994Journal of medicinal chemistry, Jul-22, Volume: 37, Issue:15
Design, synthesis and evaluation of substituted triarylnipecotic acid derivatives as GABA uptake inhibitors: identification of a ligand with moderate affinity and selectivity for the cloned human GABA transporter GAT-3.
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID728636Inhibition of [3H]GABA uptake at mouse GAT1 expressed in HEK293 cells after 3 mins by scintillation counting analysis2013Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5
Selective mGAT2 (BGT-1) GABA uptake inhibitors: design, synthesis, and pharmacological characterization.
AID454709Inhibition of GAT1 in mouse D8 cells assessed as [3H]GABA transport by liquid scintillation counting2009Bioorganic & medicinal chemistry, Sep-15, Volume: 17, Issue:18
Synthesis and biological evaluation of 4-fluoroproline and 4-fluoropyrrolidine-2-acetic acid derivatives as new GABA uptake inhibitors.
AID1615009Inhibition of mouse GAT3 expressed in HEK293 cells assessed as remaining [3H]GABA uptake at 100 uM preincubated for 25 mins followed by [3H]GABA addition and measured after 4 mins by liquid scintillation counting method relative to control2019Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5
Synthesis and biological evaluation of novel N-substituted nipecotic acid derivatives with a cis-alkene spacer as GABA uptake inhibitors.
AID539464Solubility of the compound in 0.1 M phosphate buffer at 600 uM at pH 7.4 after 24 hrs by LC/MS/MS analysis2010Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
AID1779020Inhibition of mouse GAT4 expressed in human HEK293 cell line assessed as inhibition of [3H]GABA uptake at 100 uM measured after 40 mins by LC-ESI-MS/MS analysis2021European journal of medicinal chemistry, Oct-05, Volume: 221Development of tricyclic N-benzyl-4-hydroxybutanamide derivatives as inhibitors of GABA transporters mGAT1-4 with anticonvulsant, antinociceptive, and antidepressant activity.
AID1573623Inhibition of NO711 binding to human GAT1 expressed in COS cell membranes preincubated for 25 mins by LC-ESI-MS/MS analysis2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Novel Allosteric Ligands of γ-Aminobutyric Acid Transporter 1 (GAT1) by MS Based Screening of Pseudostatic Hydrazone Libraries.
AID1337576Inhibition of mouse GAT2 expressed in HEK293 cells assessed as decrease in [3H]GABA uptake at 100 uM preincubated for 25 mins followed by [3H]GABA addition measured after 10 mins by liquid scintillation counter method2016European journal of medicinal chemistry, Nov-29, Volume: 124Synthesis and biological evaluation of a series of N-alkylated imidazole alkanoic acids as mGAT3 selective GABA uptake inhibitors.
AID774377Inhibition of GAT-1 (unknown origin)2013Journal of natural products, Oct-25, Volume: 76, Issue:10
The lignan (-)-hinokinin displays modulatory effects on human monoamine and GABA transporter activities.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1573615Competitive inhibition of human GAT1 expressed in COS cells assessed as reduction in [2H6]GABA uptake by measuring [2H6]GABA Kd(app) at 100 nM preincubated for 25 mins followed by [2H6]GABA addition and measured after 4 mins by liquid scintillation counti2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Novel Allosteric Ligands of γ-Aminobutyric Acid Transporter 1 (GAT1) by MS Based Screening of Pseudostatic Hydrazone Libraries.
AID764595Inhibition of mouse GAT4-mediated [3H]GABA uptake stably transfected in HEK293 cells assessed as residual uptake at 100 uM relative to control2013Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17
2-Substituted 4-hydroxybutanamides as potential inhibitors of γ-aminobutyric acid transporters mGAT1-mGAT4: synthesis and biological evaluation.
AID728630Anticonvulsant activity in ip dosed audiogenic seizure susceptible Frings mouse model after 60 mins2013Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5
Selective mGAT2 (BGT-1) GABA uptake inhibitors: design, synthesis, and pharmacological characterization.
AID1779022Antidepressant activity in Albino Swiss (CD-1) mouse assessed as reduction in immobility time at 30 mg/kg, ip measured for last 4 mins of 6 mins test by forced swim test relative to control2021European journal of medicinal chemistry, Oct-05, Volume: 221Development of tricyclic N-benzyl-4-hydroxybutanamide derivatives as inhibitors of GABA transporters mGAT1-4 with anticonvulsant, antinociceptive, and antidepressant activity.
AID1615007Inhibition of mouse GAT2 expressed in HEK293 cells assessed as remaining [3H]GABA uptake at 100 uM preincubated for 25 mins followed by [3H]GABA addition and measured after 10 mins by liquid scintillation counting method relative to control2019Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5
Synthesis and biological evaluation of novel N-substituted nipecotic acid derivatives with a cis-alkene spacer as GABA uptake inhibitors.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1602664Binding affinity to mouse GAT-1 expressed in HEK293 cells after 4 hrs in presence of NO711 by LC-ESI-MS/ms analysis2019Bioorganic & medicinal chemistry, 04-01, Volume: 27, Issue:7
Screening oxime libraries by means of mass spectrometry (MS) binding assays: Identification of new highly potent inhibitors to optimized inhibitors γ-aminobutyric acid transporter 1.
AID370908Inhibition of [3H]GABA uptake at mouse GAT2 expressed in HEK cells assessed as remaining [3H]GABA uptake at 100 uM relative to control2008European journal of medicinal chemistry, Nov, Volume: 43, Issue:11
Synthesis and biological evaluation of aminomethylphenol derivatives as inhibitors of the murine GABA transporters mGAT1-mGAT4.
AID1615004Inhibition of mouse GAT1 expressed in HEK293 cells assessed as reduction in [3H]GABA uptake preincubated for 25 mins followed by [3H]GABA addition and measured after 4 mins by microbeta liquid scintillation counting method2019Bioorganic & medicinal chemistry, 03-01, Volume: 27, Issue:5
Synthesis and biological evaluation of novel N-substituted nipecotic acid derivatives with a cis-alkene spacer as GABA uptake inhibitors.
AID487208Inhibition of GAT3-mediated [3H]GABA uptake in bovine brain stem2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Azetidine derivatives as novel gamma-aminobutyric acid uptake inhibitors: synthesis, biological evaluation, and structure-activity relationship.
AID1192145Inhibition of human GAT1 expressed in HEK293 cells by [3H]GABA uptake assay2015Bioorganic & medicinal chemistry, Mar-15, Volume: 23, Issue:6
Design, synthesis and SAR studies of GABA uptake inhibitors derived from 2-substituted pyrrolidine-2-yl-acetic acids.
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1346940Human GAT1 (GABA transporter subfamily)1994European journal of pharmacology, Oct-14, Volume: 269, Issue:2
Tiagabine, SK&F 89976-A, CI-966, and NNC-711 are selective for the cloned GABA transporter GAT-1.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (543)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (0.18)18.7374
1990's158 (29.10)18.2507
2000's260 (47.88)29.6817
2010's103 (18.97)24.3611
2020's21 (3.87)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 59.02

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index59.02 (24.57)
Research Supply Index6.51 (2.92)
Research Growth Index6.91 (4.65)
Search Engine Demand Index95.69 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (59.02)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials102 (17.86%)5.53%
Reviews107 (18.74%)6.00%
Case Studies56 (9.81%)4.05%
Observational1 (0.18%)0.25%
Other305 (53.42%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (14)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Characterization of [11C]Flumazenil to Image GABA Transmission in Healthy Adult Subjects and Subjects With Alcohol Dependence [NCT01904487]Phase 111 participants (Actual)Interventional2011-04-19Completed
A 12-Month, Open-Label, Flexible-Dosage Study to Evaluate the Safety and Efficacy of GABITRIL Treatment (up to 16 mg/Day) in Adults With Generalized Anxiety Disorder. [NCT00214994]Phase 30 participants Interventional2005-01-31Completed
A 12-Month, Open-Label, Flexible-Dosage Study to Evaluate the Safety of GABITRIL at Dosages up to 16mg/Day in Adults With Generalized Anxiety Disorder [NCT00233675]Phase 30 participants Interventional2003-08-31Completed
Liceo Study: A Prospective, Observational Study On The Effectiveness Of New Antiepileptic Drugs As First Bitherapy In The Daily Clinical Practice [NCT00855738]Phase 4111 participants (Actual)Interventional2007-05-31Completed
GABA Agonists as Pharmacotherapies for Cocaine Abuse [NCT00218166]Phase 278 participants (Actual)Interventional2001-08-31Completed
A 10-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Gabitril at 4, 8, and 12 mg/Day in the Treatment of Adults With Generalized Anxiety Disorder. [NCT00236015]Phase 3880 participants Interventional2004-11-30Completed
Tiagabine for the Treatment of Cocaine Dependence [NCT00086255]Phase 2140 participants Interventional2002-10-31Completed
Tiagabine for the Treatment of Cocaine Dependence in Methadone-Maintained Individuals [NCT00129298]Phase 280 participants (Actual)Interventional2004-12-31Completed
A 12-Week Open-Label Study Followed By A 24-Week Double-Blind Discontinuation Exploratory Study To Evaluate The Effects Of Gabitril™ (Tiagabine Hydrochloride) In Patients With Social Anxiety Disorder (SAD) [NCT00208741]Phase 450 participants Interventional2002-06-30Completed
A 10-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Flexible-Dosage Study to Evaluate the Efficacy and Safety of Gabitril(up to 16 mg/Day) in the Treatment of Adults With Generalized Anxiety Disorder [NCT00236067]Phase 3440 participants Interventional2004-10-31Completed
A 10-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Flexible-Dosage Study to Evaluate the Efficacy and Safety of Gabitril (up to 16 mg/Day) in the Treatment of Adults With Generalized Anxiety Disorder [NCT00236054]Phase 3440 participants Interventional2004-10-31Completed
Addition of Tiagabine to Second-Generation Antipsychotics in the Treatment of Recent-Onset Schizophrenia by Modification of Developmental Reorganization of the Prefrontal Cortex [NCT00179465]Phase 336 participants (Anticipated)Interventional2003-11-30Active, not recruiting
Population Pharmacokinetics of Antiepileptic in Pediatrics [NCT03196466]1,000 participants (Anticipated)Observational2017-06-19Recruiting
Inducing Slow Wave Sleep to Treat Obstructive Sleep Apnea [NCT02387710]Phase 218 participants (Actual)Interventional2015-03-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00855738 (17) [back to overview]Change From Baseline to Month 6 in Total Number of Days Hospitalized Because of Epilepsy
NCT00855738 (17) [back to overview]Percent Change From Baseline in the Median Number of Seizures During the Last 3 Months of Treatment
NCT00855738 (17) [back to overview]Percent of Participants Reaching Monotherapy
NCT00855738 (17) [back to overview]Percent of Participants Who Continued on Study Medication to Month 6
NCT00855738 (17) [back to overview]Time to First Seizure
NCT00855738 (17) [back to overview]Change From Baseline to Month 6 in Quality of Life 10 Domains (QOLIE-10)
NCT00855738 (17) [back to overview]Change From Baseline to Month 6 in the Hospital Anxiety and Depression Scale (HADS)
NCT00855738 (17) [back to overview]Change From Baseline to Month 6 in Visits to a Specialist or the Emergency Room Because of Epilepsy
NCT00855738 (17) [back to overview]Change From Baseline to Months 3 and 6 in Health Condition: Euro Quality of Life Scale (EQ-5D) Visual Analog Scale (VAS)
NCT00855738 (17) [back to overview]Change in Sleep Disturbances From Baseline to Month 6: Medical Outcomes Study Sleep Scale (MOS-SS)
NCT00855738 (17) [back to overview]Percent of Participants Classified as Responders
NCT00855738 (17) [back to overview]Percent of Participants Indicating Optimal Sleep on the Optimal Sleep Subscale: Medical Outcomes Study Sleep Scale (MOS-SS)
NCT00855738 (17) [back to overview]Percent of Participants That Reduced, Maintained and Increased the Doses of the Initial Treatment Administered in Monotherapy
NCT00855738 (17) [back to overview]Percent of Participants That Reduced, Maintained and Increased Their Doses of New Antiepileptic Drugs (AED)
NCT00855738 (17) [back to overview]Percent of Participants With Cessation of Occupation, Requirement of Caregiver, or Admission to Intensive Care Unit
NCT00855738 (17) [back to overview]Percent of Participants With Reduction in Number of Seizures >=25% and >=75% During the Last 3 Months of Treatment
NCT00855738 (17) [back to overview]Percent of Seizure-free Participants During the Last 3 Months Before Discontinuation
NCT02387710 (3) [back to overview]Apnea Hypopnea Index (AHI)
NCT02387710 (3) [back to overview]Arousal Threshold (Esophageal Pressure Swing)
NCT02387710 (3) [back to overview]Slow Wave Sleep (% Total Sleep Time)

Change From Baseline to Month 6 in Total Number of Days Hospitalized Because of Epilepsy

Numerical assessment of change in total number of days hospitalized because of epilepsy during the study. (NCT00855738)
Timeframe: Baseline to Month 6

InterventionDays (Mean)
All Antiepileptic Drugs-8.0

[back to top]

Percent Change From Baseline in the Median Number of Seizures During the Last 3 Months of Treatment

(NCT00855738)
Timeframe: Baseline, Month 3, Month 6 (last 3 months of treatment)

Interventionpercent change (Median)
All Antiepileptic Drugs-75.0

[back to top]

Percent of Participants Reaching Monotherapy

Percent of participants who started on more than one treatment (bitherapy) and reached monotherapy by end of study. (NCT00855738)
Timeframe: Baseline through Month 6 (or end of study)

Interventionpercent of partipants (Number)
All Antiepileptic Drugs2.9

[back to top]

Percent of Participants Who Continued on Study Medication to Month 6

Retention rate: percent of participants who continued on study medication throughout the 6 Month period after inclusion in the study. (NCT00855738)
Timeframe: Baseline to Month 6

Interventionpercent of participants (Number)
All Antiepileptic Drugs97.1

[back to top]

Time to First Seizure

Number of days to first seizure after baseline. (NCT00855738)
Timeframe: Baseline to Month 6 (or end of treatment)

Interventiondays (Mean)
All Antiepileptic Drugs35.9

[back to top]

Change From Baseline to Month 6 in Quality of Life 10 Domains (QOLIE-10)

QOLIE-10: 10-item questionnaire evaluates health-related quality of life in individuals with epliepsy. Comprised of 7 components: seizure worry, overall quality of life, emotional well-being, energy, cognitive functioning, medication effects (physical and mental effects), and social function (work, driving, social function). Total score rated 0 to 100; higher score = higher quality of life. (NCT00855738)
Timeframe: Baseline to Month 6

Interventionscores on scale (Mean)
EnergyEmotions (mood)Daily activitiesMental functionMedication effects (physical/ mental)Worry about seizures (impact of seizures)Overall quality of life
All Antiepileptic Drugs0.40.70.61.2-1.19.03.8

[back to top]

Change From Baseline to Month 6 in the Hospital Anxiety and Depression Scale (HADS)

HADS: subject rated questionnaire with 2 subscales. HADS-A assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks); HADS-D assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). Each subscale comprised of 7 items with range 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score 0 to 21 for each subscale; higher score indicates greater severity of anxiety and depression symptoms. (NCT00855738)
Timeframe: Baseline to Month 6

Interventionscores on scale (Mean)
DepressionAnxiety
All Antiepileptic Drugs-0.5-0.6

[back to top]

Change From Baseline to Month 6 in Visits to a Specialist or the Emergency Room Because of Epilepsy

Numerical assessment of change in the number of visits to a specialist or the emergency room because of epilepsy needed during the study. (NCT00855738)
Timeframe: Baseline to Month 6

Interventionvisits (Mean)
Number of visits to a specialist (n=94)Number of visits to the emergency room (n=79)
All Antiepileptic Drugs-0.6-0.3

[back to top]

Change From Baseline to Months 3 and 6 in Health Condition: Euro Quality of Life Scale (EQ-5D) Visual Analog Scale (VAS)

Assessment of the health condition of the subjects using the EQ-5D VAS: subject rated questionnaire to assess health-related quality of life in terms of a single index value. Using the VAS subjects rated current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state. (NCT00855738)
Timeframe: Baseline, Month 3, Month 6

Interventionscores on scale (Mean)
Month 3Month 6
All Antiepileptic Drugs-0.41.2

[back to top]

Change in Sleep Disturbances From Baseline to Month 6: Medical Outcomes Study Sleep Scale (MOS-SS)

Subject rated instrument to assess key constructs of sleep; assesses sleep quality and quantity. Consists of a 6-item and 9-item overall sleep problems index measuring time to fall asleep and sleep duration in past 4 weeks; 5 subscales rated 1 (all the time) to 6 (none of the time): sleep disturbance, snoring, awaken short of breath, somnolence, and adequacy. Transformed scores range = 0 to 100; higher score indicates greater intensity of attribute. Two additional subscales = sleep quantity (range 0-24 hours) and optimal sleep (number of participants with optimal sleep 7-8 hours per night). (NCT00855738)
Timeframe: Baseline to Month 6

Interventionscores on scale (Mean)
Sleep disturbanceSnoringAwake short of breathQuantityAdequacySomnolenceSleep problems (summary 6)Sleep problems (summary 9)
All Antiepileptic Drugs-1.70.01.10.22.80.6-0.9-0.9

[back to top]

Percent of Participants Classified as Responders

Responder = decrease in number of seizures by >=50 percent (%) during the last 3 months of treatment before discontinuation (assessed at Month 3 and Month 6) versus the number of seizures that occurred during the 3 months before the baseline visit (baseline). (NCT00855738)
Timeframe: Baseline, Month 3, Month 6 (last 3 months of treatment)

Interventionpercent of participants (Number)
Month 3Month 6
All Antiepileptic Drugs76.780.0

[back to top]

Percent of Participants Indicating Optimal Sleep on the Optimal Sleep Subscale: Medical Outcomes Study Sleep Scale (MOS-SS)

MOS-SS: subject rated instrument used to assess the key constructs of sleep; assesses sleep quantity and quality and is comprised of 12 items yielding 7 subscale scores and 2 composite index scores. Optimal sleep subscale is derived from sleep quantity average hours of sleep over the past 4 weeks; percent of participants with response YES (optimal) if sleep quantilty was 7-8 hours of sleep per night. (NCT00855738)
Timeframe: Baseline, Month 6

Interventionpercent of participants (Number)
BaselineMonth 6
All Antiepileptic Drugs56.565.7

[back to top]

Percent of Participants That Reduced, Maintained and Increased the Doses of the Initial Treatment Administered in Monotherapy

(NCT00855738)
Timeframe: Baseline through Month 6 (or end of treatment)

Interventionpercent of participants (Number)
ReducedMaintainedIncreased
All Antiepileptic Drugs0.0100.00.0

[back to top]

Percent of Participants That Reduced, Maintained and Increased Their Doses of New Antiepileptic Drugs (AED)

(NCT00855738)
Timeframe: Baseline to Month 6 (or end of treatment)

Interventionpercent of participants (Number)
ReducedMaintainedIncreased
All Antiepileptic Drugs0.968.530.6

[back to top]

Percent of Participants With Cessation of Occupation, Requirement of Caregiver, or Admission to Intensive Care Unit

Percent of participants with cessation of usual occupation, requirement of an informal caregiver, and who required admission to the intensive care unit (ICU). (NCT00855738)
Timeframe: Month 6

Interventionpercent of participants (Number)
Stopped Usual OccupationRequired Informal CaregiverRequired Admission to ICU
All Antiepileptic Drugs16.26.60.0

[back to top]

Percent of Participants With Reduction in Number of Seizures >=25% and >=75% During the Last 3 Months of Treatment

Percent of participants with reduction in number of seizures >=25% and >=75% during the last 3 months of treatment before discontinuation (assessed at Month 3 and Month 6) versus the 3 month period before the baseline visit. (NCT00855738)
Timeframe: Baseline, Month 3, Month 6 (last 3 months of treatment)

Interventionpercent of participants (Number)
Month 3: >=25%Month 3: >=75%Month 6: >= 25%Month 6: >=75%
All Antiepileptic Drugs86.727.886.754.4

[back to top]

Percent of Seizure-free Participants During the Last 3 Months Before Discontinuation

(NCT00855738)
Timeframe: Baseline, Month 3, Month 6 (last 3 months of treatment)

Interventionpercent of participants (Number)
Month 3Month 6
All Antiepileptic Drugs10.020.0

[back to top]

Apnea Hypopnea Index (AHI)

Number of apneas + hypopneas per hour of sleep. Hypopnea criteria: reduction in 30% of baseline flow plus 3% desaturation or arousal. (NCT02387710)
Timeframe: 1 night

Interventionevents/hour (Median)
Tiagabine39.1
Placebo40.8

[back to top]

Arousal Threshold (Esophageal Pressure Swing)

The arousal threshold was quantified as the mean of all the nadir negative esophageal pressure swings immediately preceding an arousal at the end of an obstructive apnea or hypopnea during both placebo and tiagabine nights. (NCT02387710)
Timeframe: 1 night

InterventioncmH2O (Median)
Tiagabine-27.6
Placebo-26.5

[back to top]

Slow Wave Sleep (% Total Sleep Time)

Fraction of sleep spent in stage N3 (NCT02387710)
Timeframe: 1 night

Intervention% total sleep time (Median)
Tiagabine8.3
Placebo8.8

[back to top]